



Department of Health and Human Services
Food and Drug Administration
Center for Biologics Evaluation and Research

Pharmacovigilance Plan Review Memorandum

From: Patricia Rohan, MD,
Office of Biostatistics and Epidemiology, Division of
Epidemiology, Pharmacovigilance Branch
[Please note that Branch Chief has signed on behalf of Dr. Rohan.]

Through: Meghna Alimchandani, MD,
Chief, Pharmacovigilance Branch

Scott Proestel, MD,
Director, Division of Epidemiology

To: Co-chairs:
Matthew Steele, PhD
CAPT Colleen Sweeney
Office of Vaccines Research and Review (OVRR)

Subject: BLA 125592/0

Applicant: Merck Sharp & Dohme Corp.

Product: House Dust Mites (*Dermatophagoides farinae* and
Dermatophagoides pteronyssinus) Allergen Extract
Sublingual Tablet
12 SQ-HDM
(MK-8237)
Proposed Trade Name: ODACTRA™

Proposed Indication: As immunotherapy for the treatment of house dust mite
(HDM)-induced allergic rhinitis, with or without
conjunctivitis, confirmed by positive skin test or in vitro
testing for *Dermatophagoides farinae* or *Dermatophagoides*
pteronyssinus IgE antibodies. The product is approved for
use in adults 18 through 65 years of age.

Submission Date: 09-FEB-2016

PVP Submission Date: 09-FEB-2016

Action Due Date: 08-FEB-2017

Table of Contents

| | |
|---|----|
| 1. Introduction | 3 |
| 2. Materials reviewed | 4 |
| 3. Pharmacovigilance Plan Review | 5 |
| 4. Review of other information from the managed review process..... | 6 |
| a. Non-IND trials | 6 |
| b. Pediatric Development Plan..... | 8 |
| c. Clinical safety data | 10 |
| 5. Postlicensure Safety Review..... | 34 |
| 6. Integrated Risk Assessment..... | 36 |
| 7. Recommendation | 37 |
| References | 38 |
| Addendum to OBE/DE Review | 41 |

1. Introduction

a. Objectives/Scope of the review

This memorandum is in response to a request from the Office of Vaccines Research and Review (OVRR) to the Office of Biostatistics and Epidemiology (OBE) to review the Pharmacovigilance Plan submitted by Merck Sharp & Dohme Corp. for the original BLA 125592/0 seeking initial licensure for the product MK-8237 (House Dust Mites Allergen Extract) developed as immunotherapy for the treatment of house dust mite (HDM)-induced allergic rhinitis (AR). The purpose of this review is to identify potential safety issues that may need to be addressed through postmarketing safety surveillance or further studies should the product be licensed.

a. Product description

Dust mites, 8-legged arthropods, thrive in carpeting, fabric-covered furniture and mattresses where humans shed skin – a key food source for the mites (Arlan 2001). House dust mite (HDM) antigen is a common worldwide allergen present in most geographical regions, with *D. farinae* and *D. pteronyssinus* (the most common HDM species in North America and Europe), responsible for more than 90% of HDM allergies worldwide (Thomas 2010). An estimated 84% of US homes have at least detectable levels of dust mite allergen (Portnoy 2013) and in areas where most houses have higher than 2 mcg of mite allergen per gram of dust, sensitization has consistently been found in a large proportion of children with asthma (National Academy of Sciences 2000).

HDM is the most important trigger of perennial allergic rhinitis (AR). The hypersensitivity is IgE-mediated and year round exposure to these environmental aeroallergens results in a greater disease burden due to the chronic nature of symptoms as compared to a seasonal aeroallergen.

Merck Sharp & Dohme Corp. (Sponsor), a subsidiary of Merck & Co., Inc., in collaboration with ALK-Abelló A/S (ALK), has developed a freeze-dried, sublingual pharmaceutical formulation of HDM allergen extract derived from mite (b) (4). This product, MK-8237, contains a 1:1 mixture of *Dermatophagoides farinae* [*D. farinae*/Der f/Der far] and *Dermatophagoides pteronyssinus* [*D. pteronyssinus*/Der p/Der pte] and is intended to treat HDM allergic rhinitis (AR) and allergic rhinitis with conjunctivitis (ARC).

One tablet contains 12 Development Units (DU) based upon an in-house reference, corresponding to approximately (b) (4) *D. farinae* and (b) (4) *D. pteronyssinus* (total potency of (b) (4)). The sponsor proposes the term SQ-HDM (SQ referencing potency standardization method) to replace DU for the licensed product.

Proposed Dose

MK-8237, 12 DU, is administered daily without dose escalation and current immunotherapy guidelines recommend continued treatment for at least 3 years for all allergen immunotherapy before discontinuing treatment to allow for the development of sustained clinical remission of allergic disease (Canonica 2014, Bousquet 2009).

b. Pertinent regulatory history

i. US

The product has not been licensed in the US.

| | |
|-------------|---|
| 07-APR-2012 | Original IND submitted for HDM-associated AR |
| 08-SEP-2015 | Pre-BLA Meeting for HDM-associated AR |
| 10-FEB-2015 | Pre-IND Meeting: prevention of asthma in young children |
| 09-FEB-2016 | BLA submission |

FDA Advisory Committee: No advisory committee is planned for this product.

ii. Europe

MK-8237, developed by ALK, was approved 31-August-2015, in 11 European countries (Austria, Czech Republic, Denmark, Finland, France, Germany, Italy, Norway, Poland, Slovakia and Sweden) as ACARIZAX™ (ACCARIZAX™ in Italy). The product is indicated for adults 18-65 years of age diagnosed by a clinical history and positive test for HDM sensitization with ≥1 of the following:

- Persistent moderate to severe HDM allergic rhinitis despite use of symptom relieving medication
- HDM allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe HDM allergic rhinitis and where patients' asthma status has been carefully evaluated. (Note: evaluation should include ensuring subject has a FEV1 ≥70% of predicted at initiation of treatment, has had no severe asthma exacerbations within the last 3 months, and has no ongoing respiratory tract infection.)

iii. Japan

ALK's MK-8237 was developed in collaboration with Torii Pharmaceutical Co., Ltd. (Torii) and licensed in Japan 28-SEP-2015 under the trade name of MITICURE™ for treatment of allergic rhinitis caused by house dust mites in those 12 – 64 years of age.

iv. Russia

MK-8237 (b) (4) .

v. Australia and New Zealand

MK-8237 (b) (4) .

2. Materials reviewed

a. Routine items

Module 1.11.4 Multiple Module Information Amendment - Pharmacovigilance Plan

b. Pertinent Module sections of the original licensing application selected by the reviewer

Cover Letter

Module 1.11.4 Pharmacovigilance Plan

Module 1.2 Regulatory History

Module 1.9.4 Pediatric Study Plan; Request for Partial Waiver and Partial Deferral

Module 1.14 Labeling

Module 2.5 Clinical Overview

Module 2.7.4 Summary of Clinical Safety

Module 2.7.6 Synopses of Individual Studies

Module 5.2 Tabular Listing of All Clinical Studies

Module 5.3.5.3.3 Integrated Analysis of Safety (ISS)

c. Other items reviewed

| | |
|-------------|--|
| 125592/0.1 | Request for Proprietary Name Review |
| 125592/0.8 | Safety Update Report (International Postmarketing Experience) Reporting period: 15-Apr-2015 to 9-Apr-2016 |
| 125592/0.9 | Revised ISS tables restricted to 12 DU dose recipients, patients 18-65 years of age and >65 years of age, reported separately Submitted in response to FDA Information Request of May 25, 2016 |
| 125592/0.48 | Safety data for subjects in Phase 2 and Phase 3 studies who were crossed over to treatment other than that to which they were originally assigned at randomization, submitted in response to FDA Information Request of December 14, 2016. [See Addendum to this review] |

3. Pharmacovigilance Plan Review

a. Clinical safety database (see review below)

b. Safety concerns including planned pharmacovigilance and sponsor's proposals

i. Important identified safety issues

- Serious systemic allergic reactions, including anaphylactic reactions
- Local allergic reactions with potential to compromise airway
- Acute worsening of asthma symptoms (exacerbations)

Manufacturer's Planned Actions for all identified safety issues:

Routine pharmacovigilance, use of an event-specific follow-up questionnaire
Appropriate US PI and Medication Guide information

ii. Important potential safety issues

- Anaphylactic shock
- Eosinophilic esophagitis (EoE)

Planned Actions for all potential safety issues:

Routine pharmacovigilance, use of an event-specific follow-up questionnaire
Appropriate US PI and Medication Guide information

iii. Important missing information

- Pregnancy, lactation
- Use in children (<18 years of age)
- Use in elderly (> 65 years of age)
- Use in severe, unstable or uncontrolled asthma
- Co-administration with other sublingual immunotherapy (SLIT) products

Manufacturer's Planned actions for all important missing information:

House Dust Mites (*Dermatophagoides farinae* and *Dermatophagoides pteronyssinus*) Allergen Extract (MK-8237) Proposed Trade Name: ODACTRAM

Routine pharmacovigilance

Appropriate US label language

Study in children and adolescents ages 5-17 years (see Section 4.b., below)

c. **Review of Postmarketing Study proposal or protocol synopsis**

Protocol Title: Post-Market Claims and EMR Based Study of Serious Allergic

Reactions and Eosinophilic Esophagitis in Marketed Use of MK-8237 in the United States

Two Phase 4 studies are planned under this PMC at this time: a claims-based study (from a large US health insurance database) and electronic medical record studies (from a large US integrated health system) will aim to assess general safety and specifically assess the risks of:

- Systemic allergic reactions, including anaphylactic reactions / anaphylactic shock
- Serious allergic reactions including local reaction w/ potential to compromise airway
- Eosinophilic esophagitis (EoE)
- Acute worsening of asthma symptoms

These studies will be incorporated into the database already being used for GRASTEK ((Timothy Grass Pollen Allergen Extract) Tablet for Sublingual Use, approved April 11, 2014) and RAGWITEK ((Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use, approved April 17, 2014). Based upon experience with US uptake of these two products, the sponsor estimates uptake for the DM product at (b) (4) patients over 3 years.

The study protocol, including any synopsis, will be submitted and milestones for this study will be determined after discussion between the sponsor and FDA.

4. Review of other information from the managed review process

a. Non-IND trials

Five clinical trials (P011/MT-01, P012/MT-02, P013/MT-03, P014/MT-04, and P015/MT-06) were conducted with MK-8237 by Merck's Partner, ALK-Abelló A/S. These foreign clinical trials were not conducted under US IND and studied MD-8237 use in asthmatics. The safety data are submitted to the BLA as supportive.

Summary of serious adverse events from clinical studies conducted in Japan

Full study reports are not available to Merck, only summary information on SAEs. No deaths were reported in any of the 3 Torii studies: TO-201 (Phase 1 study of 48 males with asthma); TO-203-AR (Phase 3 study of 946 allergic rhinitis subjects) and TO-203-AA (Phase 3 study of 824 subjects with allergic asthma).

No SAEs were reported in the Torii Phase 1 study and fifty-one SAEs were reported in forty-three subjects in the two Torii Phase 3 studies:

SAEs in fifteen subjects receiving MK-8237 (12 DU)

- Incisional hernia
- Sudden hearing loss
- Gastroenteritis
- Ovarian neoplasm

House Dust Mites (Dermatophagoides farinae and Dermatophagoides pteronyssinus) Allergen Extract
(MK-8237) Proposed Trade Name: ODACTRAM

- Breast cancer
- Alanine and aspartate aminotransferases increased, hepatic function abnormal
- Gastric cancer
- Asthma (onset: Day 163)
- Alanine aminotransferase increased, liver disorder
- Breast cancer
- Cervical dysplasia
- Anal fissure
- Back pain
- Abortion
- Arthroscopy

SAEs in twelve subjects receiving MK-8237 (6 DU)

- Tonsillitis
- Hemorrhoid operation
- Tooth hypoplasia
- Ulnar fracture
- Appendicitis
- Humerus fracture
- Blood pressure decreased
- Intervertebral disc protrusion
- Cervical dysplasia
- Pneumonia bacterial
- Abortion
- Enterocolitis

SAEs in sixteen subjects receiving placebo

- Contusion, haematoma evacuation
- Anaphylactic reaction (Day 74)
- Gastric cancer
- Premature labor, low birth weight baby, Apgar score low
- Pain
- Asthma (Day 37)
- Diverticulitis
- Gastroenteritis
- Influenza
- Osteonecrosis
- Enterocolitis
- Alanine and aspartate aminotransferases increased, autoimmune hepatitis*
- Pelvic infection
- Sudden hearing loss
- Imminent abortion
- Uterine leiomyoma

*SAEs reported as drug-related by the sponsor

b. Pediatric Development Plan**Partial Waiver**

A Partial Waiver is requested for the age range below 5 years of age as:

- The drug product does not represent a meaningful therapeutic benefit over existing therapies for children under the age of 5 years.
- Necessary studies are impossible or highly impracticable because the number of children younger than 5 years of age with allergic rhinitis who have been diagnostically confirmed with sensitivity to house dust mite is too small.
- Additionally, immunotherapy for AR/ARC is not likely to be used in a substantial ($\geq 50,000$ patients in the US) number of very young children.

Partial Deferral

A Partial Deferral to the pediatric requirement in children 5 to < 17 years of age is requested. The sponsor plans to conduct the following studies in support of use in this age group with a database of approximately 1000 subjects, 5-17 years of age, using 12 DU MK-8237 for at least 28 days):

Completed pediatric study:

Phase 1 Safety Study in 12-17 year olds (see Section 4.c.i., below)

Planned pediatric study #1:

Phase 3, double-blind, parallel-group, placebo-controlled trial to evaluate safety, tolerability, and efficacy of MK-8237 in pediatric subjects (5 - 17 years of age) with HDM-induced AR with or without asthma

Sample size: N ~ 580

Entry criteria

1. ≥ 5 and ≤ 17 years of age
2. ≥ 6 month history of HDM-induced allergic rhinitis/rhinoconjunctivitis (with or without asthma) requiring anti-allergy treatment during the prior year.
3. Positive skin prick test (average wheal diameter of two tests must be ≥ 5 mm larger than saline control) to *D. pteronyssinus* and/or *D. farinae* at screening.
4. Specific *D. pteronyssinus* and/or *D. farinae* IgE of \geq Class 2 [0.7 kU/L] at screening
5. FEV1 $\geq 80\%$ of predicted at Screening, Run-in, and Randomization Visits (following ≥ 6 hour wash-out of short acting beta2 agonist or ≥ 12 hour wash-out of long-acting beta-2 agonist)
6. Meeting symptom threshold during Run-in period
7. No immunosuppressive treatment within 3 months prior to screening
8. No unstable or severe asthma or prior life-threatening asthma attack or an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalization, or treatment with systemic corticosteroids at any time within 3 months prior to screening visit
9. No asthma requiring high-dose inhaled corticosteroids (ICS) within 6 months prior to screening
10. No history of anaphylaxis with cardiorespiratory symptoms due to prior immunotherapy, unknown cause, or inhalant allergy
11. No history of chronic urticaria and/or angioedema within 2 years prior to screening and run-in
12. No immunotherapy with HDM allergen for >1 month and within 5 years prior to screening
13. No prior exposure to MK-8237
14. No ongoing treatment with any specific immunotherapy

House Dust Mites (*Dermatophagoides farinae* and *Dermatophagoides pteronyssinus*) Allergen Extract
(MK-8237) Proposed Trade Name: ODACTRAM

15. No history of allergy, hypersensitivity or intolerance to investigational medicinal products (except for *D. pteronyssinus* and/or *D. farinae*), rescue medications, self-injectable epinephrine
16. Not nursing, pregnant or expecting to conceive during the study

Run-in Period

- Daily symptoms recorded in an e-diary for up to 6 weeks
- Symptoms scores will determine whether a subject meets an appropriate symptom threshold during a time when they are expected to have natural exposure to HDM and when allergy relieving medications have been temporarily interrupted following a washout.
- In temperate climates, this period is intended not to overlap with pollen seasons in order to minimize exposure to non-HDM allergens, which may also cause allergic rhinitis symptoms
- This pre-randomization period may last for up to ~ 1 year

Treatment

MK-8237 12 DU or placebo daily for up to ~ 52 weeks (equal randomization), with the majority of subjects anticipated to receive a total of 32-40 weeks of treatment

Safety Evaluations (including induction and efficacy assessment period)

- Safety will be monitored as in P001, the adult pivotal Phase 3 trial:
 - AE collection cards Days 1-28 for all adverse events and to prompt for AEs associated with sublingual immunotherapy; filled out daily by subjects or parents
 - eCRFs will capture AEs reported during office visits or telephone contacts
- Symptoms and use of study reliever (symptomatic rescue) medication will be recorded during the last 12 weeks of treatment in daily electronic diary (e-diary)
- The last 8 weeks of the Treatment phase will be used as the efficacy assessment period, as this period is anticipated to occur when there is limited interference by other aeroallergens (e.g., pollens), HDM exposure is predominant, and subjects are affected most by HDM-induced AR symptoms.

Study Timeline

| | |
|---------------------|---------|
| Protocol submission | 4Q 2017 |
| Start Screening | 4Q 2018 |
| Start Randomization | 4Q 2019 |

Efficacy Assessments

| | |
|---------------------------|---|
| Cohort 1 HDM peak season | 2020-2021 |
| Cohort 2* HDM peak season | 2021-2022 |
| Last patient visit | 1Q 2021* |
| Submission of CSR | 3Q 2021* |
| Supplemental BLA | 3Q 2022 (if a 2 nd season is required) |

*Extension of the study to a second season may be required depending on ability to randomize a sufficient number of subjects and deliver adequate induction prior to the efficacy peak HDM seasons.

Planned pediatric study #2:

Phase 3 double-blind, parallel-group, placebo-controlled trial to further evaluate the safety and tolerability of MK-8237 in pediatric subjects (5 to 17 years of age) with HDM-induced AR/ARC with or without asthma

- Approximately ~270 pediatric subjects will be treated over a longer duration of 28 - 52 weeks

House Dust Mites (*Dermatophagoides farinae* and *Dermatophagoides pteronyssinus*) Allergen Extract (MK-8237) Proposed Trade Name: ODACTRAM

- AE collection cards will be filled out daily by subjects or parents, Days 1-28, to collect AEs as well as to prompt for AEs associated with sublingual immunotherapy
- Descriptive study, no hypothesis testing, endpoints or thresholds to trigger additional action

Study Timeline

| | |
|---------------------|---------|
| Protocol submission | 4Q 2017 |
| Start Screening** | 1Q 2020 |
| Start Randomization | 4Q 2020 |
| Last patient visit | 1Q 2022 |
| Submission of CSR | 3Q 2022 |
| sBLA submission | 3Q 2022 |

** Screening of Efficacy and Safety trials will be separated to avoid competition for recruitment between them.

c. Clinical safety data

i. Clinical Overview

The US clinical program for the development of MK-8237 for treatment of HDM-induced allergic rhinitis, with or without conjunctivitis, encompasses eight randomized, double-blind, placebo-controlled studies: three phase 1 studies, two phase 2 studies and three phase 3 studies.

Please note: DE defers to OVRP for full clinical review of premarket clinical safety database.

| Table 1: Overview of MK-8237 clinical studies | | | | | | | | | | |
|---|-------|------------|-----------------|--------|----------|--------------|------------|-------------------|---------------------|-------------|
| Study | | | | | | | | Population | | |
| Protocol | Phase | Location | Number enrolled | Safety | Efficacy | Dose-finding | Duration | Allergic rhinitis | Rhinoconjunctivitis | Age (years) |
| P011 / MT-01 ^{1,4} | 1 | Europe | 71 | X | | | 28 days | +/- | +/- | 18-65 |
| P013 / MT-03 ^{1,4} | 1 | Europe | 72 | X | | X | 28 days | +/- | NS | 5-14 |
| P008 ⁵ | 1 | N. America | 195 | X | | | 28 days | X | X | 12-17 |
| P012 / MT-02 ^{1,4} | 2 | Europe | 604 | X | X | X | 12 months | X | NS | ≥14 |
| P003 ^{3,5} | 2 | Europe | 124 | X | X | X | 6 months | X | X | ≥18 |
| P014 / MT-04 ^{1,4} | 3 | Europe | 834 | X | X | | 14 months | X | NS | ≥18 |
| P015 / MT-06 ^{2,4} | 3 | Europe | 992 | X | X | | 12 months | X | NS | 18-65 |
| P001 ⁵ | 3 | N. America | 1482 | X | X | | ≤12 months | X | X | ≥12 |
| 1. Supportive safety data from non-IND studies (treatment of allergic asthma ± allergic rhinitis) included in this BLA. 2. Supportive safety data from non-IND Phase 3 study (allergic rhinitis ± allergic asthma) included in this BLA 3. Environmental chamber challenge; 4. ALK sponsored trial; 5. Merck sponsored trial NS: Not specified From STN 125592, Module 2.5, Table 2.5:1 and Module 2.7.4, Table 2.7.4:1 | | | | | | | | | | |

Events of clinical interest (ECIs) actively monitored during trials:

- Anaphylactic reactions, anaphylaxis and/or systemic allergic reactions

House Dust Mites (*Dermatophagoides farinae* and *Dermatophagoides pteronyssinus*) Allergen Extract
(MK-8237) Proposed Trade Name: ODACTRAM

- The assessment of anaphylaxis was guided by the recommendations in the Food Allergy & Anaphylaxis Network (FAAN) Report which proposed clinical criteria that would increase diagnostic precision in anaphylaxis (Sampson 2005; Sampson 2006).
- Events treated with epinephrine
- Severe local swelling or edema of the mouth and/or throat
- AST or ALT laboratory value greater than or equal to 3X the upper limit of normal and an elevated total bilirubin laboratory value greater than or equal to 2X the upper limit of normal.
- Overdose: above prescribed dose without associated clinical or laboratory abnormalities

Overview of treatment including dose ranging across studies

A total of 2734 subjects with a history of HDM allergy (allergic rhinitis/allergic rhinoconjunctivitis [AR/C] and/or asthma) received at least one dose of MK-8237 (0.5-32 DU) in randomized trials, with treatment durations ranging from a single dose to daily doses for up to approximately 18 months.

Study MT-01 evaluated MK-8237 doses from 0.5 – 32 DU. The 32 DU dose group was discontinued after one subject developed vomiting 15 minutes following tablet administration. After completion of study MT-01, the 16 DU dose was not further investigated due to the persistent nature of local adverse events which included swelling, moderate throat tightness and severe mouth oedema. There were no severe local swellings at doses lower than 16 DU, thus the 6 DU and 12 DU doses were selected for study in Phase 2 and 3 trials.

Overview of safety data across studies

The safety analysis population included all randomized subjects based upon treatment group assignment. Phase 2 and Phase 3 safety data were pooled to better characterize the safety profile of MK-8237 and includes subjects treated with 6 DU, 12 DU, and placebo doses. Studies MT-02 and MT-04 enrolled asthmatics who also had HDM allergic Rhinoconjunctivitis; studies P003, MT-06 and P001 enrolled individuals with HDM allergic rhinoconjunctivitis, many also had asthma.

Extent of exposure to the study drug

Phase 1 studies MT-01 and MT-03 were designed to study MK-8237 doses from 0.5 to 32 DU daily; however, the 32 DU dose group was discontinued after a single subject developed vomiting 15 minutes after tablet administration. The 16 DU dose was associated with persistent local adverse events including swellings (not further described), one occurrence of moderate throat tightness and two occurrences of severe mouth oedema, and the two subsequent Phase I trials, MT-03 and P008 evaluated doses up to 12 DU.

Phase 2 and Phase 3 subjects received 6 DU, 12 DU or placebo daily as summarized in the following table.

| Table 2: Extent of Exposure – Phase 2 and Phase 3 studies ¹ | | |
|--|-----------------|----------------|
| | MK-8237 (12 DU) | MK-8237 (6 DU) |
| Subjects¹ in population | 1383 | 808 |
| Duration of exposure ² (days) | | |
| Mean | 281.4 | 345.4 |

House Dust Mites (Dermatophagoides farinae and Dermatophagoides pteronyssinus) Allergen Extract
(MK-8237) Proposed Trade Name: ODACTRAM

| Table 2: Extent of Exposure – Phase 2 and Phase 3 studies¹ | | |
|--|------------------------|-----------------------|
| | MK-8237 (12 DU) | MK-8237 (6 DU) |
| Subjects¹ in population | 1383 | 808 |
| SD | 125.8 | 111.64 |
| Median | 300.5 | 363 |
| Range | 0 to 550 | 0 to 550 |
| 1. All randomized subjects except MT-02 where only those randomized to MK-8237 (6 DU) and placebo are included 2. Each subject counted once in each applicable dose category column and duration of exposure row. 3. Duration of exposure was calculated assuming one day of dosing = 1 day of exposure. From STN 125592.0, Module 5.3.5.3.3, Table 1 | | |

Demographic data

Subjects were predominantly young, White adults, as illustrated in the following table summarizing the Phase 2 and Phase 3 populations.

| Table 3: Demographic and other characteristics of Phase 2 and Phase 3 study subjects¹ | | | | | | | |
|--|----------------------------------|----------------------|------------|---------------------|------------|----------------|------------|
| | | MK-8237 12 DU | | MK-8237 6 DU | | Placebo | |
| | | n | (%) | n | (%) | n | (%) |
| Subjects in population | | 1,383 | (100) | 808 | (100) | 1,540 | (100) |
| Gender | Male | 629 | (45.5) | 392 | (48.5) | 728 | (47.3) |
| | Female | 754 | (54.5) | 416 | (51.5) | 812 | (52.7) |
| Age (Years) | 12 to <18 | 95 | (6.9) | 9 | (1.1) | 106 | (6.9) |
| | 18 to <50 | 1,105 | (79.9) | 719 | (89.0) | 1,247 | (81.0) |
| | 50 to <65 | 169 | (12.2) | 72 | (8.9) | 164 | (10.6) |
| | ≥65 | 14 | (1.0) | 8 | (1.0) | 23 | (1.5) |
| | Mean | 33.8 | | 32.4 | | 33.6 | |
| | SD | 12.7 | | 11.5 | | 12.7 | |
| | Median | 32.0 | | 30.0 | | 32.0 | |
| | Range | 12 to 77 | | 15 to 75 | | 12 to 85 | |
| Race | American Indian or Alaska Native | 6 | (0.4) | 0 | (0.0) | 4 | (0.3) |
| | Asian | 56 | (4.0) | 7 | (0.9) | 55 | (3.6) |
| | Black or African American | 82 | (5.9) | 2 | (0.2) | 78 | (5.1) |
| | Multi-Racial | 39 | (2.8) | 1 | (0.1) | 46 | (3.0) |
| | Other | 2 | (0.1) | 7 | (0.9) | 6 | (0.4) |
| | White | 1,195 | (86.4) | 791 | (97.9) | 1,347 | (87.5) |
| | Unknown/Missing | 3 | (0.2) | 0 | (0.0) | 4 | (0.3) |
| | Hispanic or Latino | 71 | (5.1) | 1 | (0.1) | 68 | (4.4) |
| | Not Hispanic or Latino | 1,301 | (94.1) | 807 | (99.9) | 1,451 | (94.2) |
| | Unknown/Missing | 11 | (0.8) | 0 | (0.0) | 21 | (1.4) |
| Allergic characteristics | With asthma | 686 | (49.6) | 594 | (73.5) | 2,100 | (56.4) |
| | Sensitized to HDM only | 394 | (28.5) | 224 | (27.7) | 415 | (26.9) |
| | Sensitized to HDM and others | 987 | (71.4) | 581 | (71.9) | 1,117 | (72.5) |
| 1. All randomized subjects except MT-02 where only those randomized to MK-8237 (6 DU) and placebo are included From STN 125592.0, Module 5.3.5.3.3 Table 10 and Table | | | | | | | |

House Dust Mites (*Dermatophagoides farinae* and *Dermatophagoides pteronyssinus*) Allergen Extract
(MK-8237) Proposed Trade Name: ODACTRAM

Subject disposition

The proportion of subjects completing the studies was highest in the placebo groups (83.0% overall in Phase 2 and Phase 3 studies), and lowest in the MK-8237 (12 DU) treatment group (78.5% overall in Phase 2 and Phase 3 studies).

In the Phase 1 clinical trials, 9 subjects (1 in MT-01 and 8 in P008) discontinued due to AEs, all considered drug related by the manufacturer, and all classified as non-serious. In Phase 2 and Phase 3 clinical trials, a total of 180 subjects (4.8%) discontinued due to AEs. The percentage of discontinuations due to AEs was greater in the 12 DU group (n=113; 8.2%) than in the 6 DU group (n=26; 3.2%), and least in the placebo group (n=40; 2.6%) as seen in the table below.

| Table 4: Disposition of all Phase 2 and Phase 3 study subjects¹ | | | | | | |
|---|------------------------|----------|-----------------------|----------|-----------------|----------|
| | MK-8237 (12 DU) | | MK-8237 (6 DU) | | Placebo | |
| | N = 1383 | | N = 808 | | N = 1540 | |
| | n | % | n | % | n | % |
| Completed | 1086 | 78.5 | 676 | 83.7 | 1278 | 83.0 |
| Discontinued | 296 | 21.4 | 132 | 16.3 | 262 | 17.0 |
| Adverse event | 114 | 8.2 | 26 | 3.2 | 40 | 2.6 |
| Lack of efficacy | 2 | 0.1 | 3 | 0.4 | 4 | 0.3 |
| Lost to follow-up | 46 | 3.3 | 16 | 2.0 | 44 | 2.9 |
| Non-Compliance with study drug | 0 | 0.0 | 0 | 0.0 | 5 | 0.3 |
| Other | 31 | 2.2 | 34 | 4.2 | 35 | 2.3 |
| Physician decision | 2 | 0.1 | 0 | 0.0 | 3 | 0.2 |
| Pregnancy | 3 | 0.2 | 2 | 0.2 | 16 | 1.0 |
| Progressive disease | 1 | 0.1 | 0 | 0.0 | 0 | 0.0 |
| Protocol violation | 14 | 1.0 | 12 | 1.5 | 21 | 1.4 |
| Technical problems | 0 | 0.0 | 0 | 0.0 | 1 | 0.1 |
| Withdrawal by subject | 83 | 6.0 | 39 | 4.8 | 93 | 6.0 |
| Status not recorded | 1 | 0.1 | 0 | 0.0 | 0 | 0.0 |
| Treatment interruption | 138 | 9.9 | 89 | 11.0 | 80 | 5.2 |

1. All randomized subjects except MT-02 (MK-8237, 6 DU and placebo subjects only). Subject classified by last recorded disposition
From STN 125592.0, Module 2.5, Table 12, Module 5.3.5.3.3, Table 9

Safety data from Phase 2 and Phase 3 studies

A dose-response was seen in the rates of overall AEs (82.9%, 68.6% and 63.6%) and of drug-related AEs (68.8%, 44.1% and 27.5%), but not in the overall rates of SAEs (1.2%, 2.5% and 2.0%) in the 12 DU, 6 DU and placebo groups, respectively.

House Dust Mites (Dermatophagoides farinae and Dermatophagoides pteronyssinus) Allergen Extract
(MK-8237) Proposed Trade Name: ODACTRAM

| Table 5a: Overview of adverse events in Phase 2 and Phase 3 studies¹ | | | | | | |
|---|-------------|--------|------------|--------|-------------|--------|
| Category | 12 DU | | 6 DU | | Placebo | |
| | N (%) | | N (%) | | N (%) | |
| Total subjects | 1382 | | 808 | | 1540 | |
| Any adverse event | 1146 | (82.9) | 554 | (68.6) | 979 | (63.6) |
| Death | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Serious adverse event ⁵ | 17 | (1.2) | 20 | (2.5) | 31 | (2.0) |
| Discontinued due to an adverse event | 113 | (8.2) | 26 | (3.2) | 41 | (2.7) |
| Discontinued ² due to a serious adverse event | 5 | (0.4) | 3 | (0.4) | 10 | (0.6) |
| Drug-related ³ adverse event | 951 | (68.8) | 356 | (44.1) | 423 | (27.5) |
| Drug-related ³ serious adverse event | 3 | (0.2) | 2 | (0.2) | 2 | (0.1) |
| Drug-related ³ adverse event leading to discontinuation | 113 | (8.2) | 26 | (3.2) | 41 | (2.7) |
| Drug-related ³ serious adverse event leading to discontinuation ^{4,5} | 1 | (0.1) | 0 | (0.0) | 2 | (0.1) |

1. All randomized subjects except study MT-02 where only MK-8237 (6 DU) & placebo recipients are included; 2. Study medication withdrawn;
3. Determined by the investigator to be related to the study drug;
4. Two subjects (12 DU group) had accidental overdoses, i.e., total daily dose of 24 DU, and subsequent development of mild adverse events (oral pruritus and throat irritation in one subject and oral pain in the other). In Merck-sponsored trials, reports of adverse events associated with an overdose were classified as serious for safety monitoring; reports of overdose without additional adverse events were classified as non-serious events of clinical interest (ECI). Adverse events reported for the two subjects identified as having had an accidental overdose are not listed in this table as serious as they did not meet International Conference on Harmonisation (ICH) criteria for seriousness. Adverse events for both subjects assessed as drug-related by the investigator.
From STN 125592.0, Module 2.5, Table 2.5: 13

In response to FDA/OVRR's request, the sponsor additionally provided these data from adults in Phase 2 and Phase 3 studies who received MK-8273 12 DU dose, with those 18-65 years of age and those >65 years of age reported separately. There do not appear to be any notable differences between the results in Table 5b, below, as compared to Table 5a, above. The numbers of individuals in the >65 years of age group are quite small, making it difficult to draw any useful conclusions from those results.

| Table 5b: Overview of adverse events in adults in Phase 2 and Phase 3 studies¹ - 12 DU dose | | | | | | |
|---|--------------------|--------------|------------------|-----------|--|--|
| Category | 18-65 years of age | | >65 years of age | | | |
| | 12 DU | Placebo | 12 DU | Placebo | | |
| | N (%) | N (%) | N (%) | N (%) | | |
| Total subjects | 1,277 | 1,282 | 11 | 20 | | |
| Any adverse event | 1,047 (82.0) | 811 (63.3) | 10 (90.9) | 16 (80.0) | | |
| Death | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | | |
| Serious adverse event ⁵ | 16 (1.3) | 23 (1.8) | 1 (9.1) | 2 (10.0) | | |
| Discontinued due to an adverse event | 104 (8.1) | 38 (3.0) | 0 (0.0) | 1 (5.0) | | |
| Discontinued ² due to a serious adverse event | 5 (0.4) | 8 (0.6) | 0 (0.0) | 1 (5.0) | | |
| Drug-related ³ adverse event | 857 (67.1) | 351 (27.4) | 7 (63.6) | 7 (35.0) | | |
| Drug-related ³ serious adverse event | 3 (0.2) | 2 (0.2) | 0 (0.0) | 0 (0.0) | | |
| Drug-related ³ adverse event leading to discontinuation | 82 (6.4) | 11 (0.9) | 0 (0.0) | 0 (0.0) | | |
| Drug-related ³ serious adverse event leading to discontinuation ^{4,5} | 1 (0.1) | 2 (0.2) | 0 (0.0) | 0 (0.0) | | |

1. Adult recipients receiving MK-8273 (12 DU dose) in Studies MT-04, P003, MT-06, P001
2. Study medication withdrawn
3. Determined by the investigator to be related to the study drug
4. Two subjects had an accidental overdose (each with total daily dose of 24 DU) and subsequent development of mild adverse events (oral pruritus and throat irritation in one subject, and oral pain in the other subject). In Merck-sponsored trials, reports of adverse events associated with an overdose were classified as serious for safety monitoring; reports of overdose without additional adverse events were classified as non-serious events of clinical interest (ECI). The adverse events reported for the two subjects identified as having had an accidental overdose are not listed in this table as serious as they did not meet International Conference on Harmonisation (ICH) criteria for seriousness. The adverse events for both subjects were assessed as drug-related by the investigator.
From STN 125592.0009, Table 1 (selected ISS data restricted to 12 DU dose adult recipients)

The most commonly reported AEs classified as drug-related by the manufacturer were events localized in or around the mouth, in the throat, or in the ear and showed a dose-response relationship to MK-8237 dose. The three most commonly reported specific AEs by MedDRA Preferred Term, each occurring in $\geq 15\%$ of subjects in the 12 DU group, were ear pruritus, oral pruritus, and throat irritation. The median time from treatment initiation to onset in the 12 DU group was 1 day with median duration ranging between 30-42 minutes for these AEs.

| Table 6a: Adverse events in Phase 2 and Phase 3 studies¹ by SOC and PT (incidence > 2% in any treatment group) | | | | | | |
|---|------------------------------------|----------|---------------------------------|----------|------------------------------|----------|
| | MK-8237 12 DU N = 1,383 | | MK-8237 6 DU N = 808 | | Placebo N = 1,540 | |
| | n | % | n | % | n | % |
| Subjects reporting ≥ 1 adverse event | 1,146 | (82.9) | 554 | (68.6) | 979 | (63.6) |
| Ear and labyrinth disorders | 427 | (30.9) | 43 | (5.3) | 102 | (6.6) |
| Ear pruritus | 413 | (29.9) | 33 | (4.1) | 95 | (6.2) |
| Eye disorders | 61 | (4.4) | 23 | (2.8) | 64 | (4.2) |
| Eye pruritus | 28 | (2.0) | 5 | (0.6) | 22 | (1.4) |
| Gastrointestinal disorders | 867 | (62.7) | 306 | (37.9) | 359 | (23.3) |
| Abdominal pain upper | 100 | (7.2) | 10 | (1.2) | 48 | (3.1) |
| Diarrhoea | 67 | (4.8) | 7 | (0.9) | 31 | (2.0) |
| Dyspepsia | 34 | (2.5) | 16 | (2.0) | 0 | (0.0) |
| Glossodynia | 133 | (9.6) | 13 | (1.6) | 28 | (1.8) |
| Lip oedema | 28 | (2.0) | 9 | (1.1) | 4 | (0.3) |
| Lip swelling | 161 | (11.6) | 14 | (1.7) | 20 | (1.3) |
| Mouth swelling | 83 | (6.0) | 10 | (1.2) | 12 | (0.8) |
| Mouth ulceration | 85 | (6.1) | 0 | (0.0) | 30 | (1.9) |
| Nausea | 134 | (9.7) | 4 | (0.5) | 62 | (4.0) |
| Oedema mouth | 59 | (4.3) | 61 | (7.5) | 1 | (0.1) |
| Oral pruritus | 594 | (43.0) | 136 | (16.8) | 131 | (8.5) |
| Palatal swelling | 82 | (5.9) | 0 | (0.0) | 11 | (0.7) |
| Paraesthesia oral | 106 | (7.7) | 42 | (5.2) | 24 | (1.6) |
| Stomatitis | 31 | (2.2) | 9 | (1.1) | 15 | (1.0) |
| Swollen tongue | 137 | (9.9) | 8 | (1.0) | 18 | (1.2) |
| Tongue pruritus | 67 | (4.8) | 33 | (4.1) | 14 | (0.9) |
| Tongue ulceration | 96 | (6.9) | 0 | (0.0) | 22 | (1.4) |
| Vomiting | 36 | (2.6) | 3 | (0.4) | 15 | (1.0) |
| General disorders and administration site conditions | 82 | (5.9) | 28 | (3.5) | 70 | (4.5) |
| Infections and infestations | 474 | (34.3) | 314 | (38.9) | 526 | (34.2) |
| Bronchitis | 43 | (3.1) | 31 | (3.8) | 46 | (3.0) |
| Influenza | 34 | (2.5) | 25 | (3.1) | 32 | (2.1) |
| Nasopharyngitis | 164 | (11.9) | 137 | (17.0) | 188 | (12.2) |
| Pharyngitis | 43 | (3.1) | 32 | (4.0) | 46 | (3.0) |
| Respiratory tract infection | 10 | (0.7) | 20 | (2.5) | 16 | (1.0) |
| Sinusitis | 42 | (3.0) | 19 | (2.4) | 42 | (2.7) |
| Upper respiratory tract infection | 93 | (6.7) | 36 | (4.5) | 116 | (7.5) |
| Viral infection | 22 | (1.6) | 18 | (2.2) | 15 | (1.0) |
| Injury, poisoning and procedural complications | 105 | (7.6) | 35 | (4.3) | 118 | (7.7) |
| Accidental overdose | 44 | (3.2) | 6 | (0.7) | 41 | (2.7) |

**Table 6a: Adverse events in Phase 2 and Phase 3 studies¹ by SOC and PT
(incidence > 2% in any treatment group)**

| | | | | | | |
|---|-----|--------|-----|--------|-----|--------|
| Musculoskeletal and connective tissue disorders | 74 | (5.4) | 32 | (4.0) | 69 | (4.5) |
| Nervous system disorders | 164 | (11.9) | 52 | (6.4) | 128 | (8.3) |
| Dysgeusia | 76 | (5.5) | 1 | (0.1) | 29 | (1.9) |
| Headache | 50 | (3.6) | 29 | (3.6) | 77 | (5.0) |
| Respiratory, thoracic and mediastinal disorders | 718 | (51.9) | 211 | (26.1) | 394 | (25.6) |
| Asthma | 40 | (2.9) | 44 | (5.4) | 57 | (3.7) |
| Cough | 35 | (2.5) | 17 | (2.1) | 36 | (2.3) |
| Dyspnoea | 26 | (1.9) | 21 | (2.6) | 29 | (1.9) |
| Oropharyngeal pain | 39 | (2.8) | 21 | (2.6) | 29 | (1.9) |
| Pharyngeal oedema | 123 | (8.9) | 11 | (1.4) | 23 | (1.5) |
| Rhinitis allergic | 20 | (1.4) | 27 | (3.3) | 32 | (2.1) |
| Throat irritation | 603 | (43.6) | 91 | (11.3) | 192 | (12.5) |
| Skin and subcutaneous tissue disorders | 95 | (6.9) | 43 | (5.3) | 98 | (6.4) |

1. All randomized subjects except study MT-02 where only MK-8237 (6 DU) & placebo recipients are included
Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

For MT-02, only subjects randomized to MK-8237 6 DU and placebo were included.

From STN 125592.0, Module 2.7.4, Table 16

In response to FDA/OVRR's request, the sponsor additionally provided these data from adults in Phase 2 and Phase 3 studies who received MK-8273 12 DU dose, with those 18-65 years of age and those >65 years of age reported separately. There do not appear to be any notable differences between the results in Table 6b, below, as compared to Table 6a, above, although the incidence of several events rise above the 2% cutoff in the adult-only group and are listed in Table 6b, e.g., various cardiac disorders, although the database is underpowered to detect significant differences between groups. As in Table 5b, the numbers of individuals in the >65 years of age group are quite small, making it difficult to draw any useful conclusions from those results.

**Table 6b: Adverse events in in adults in Phase 2 and Phase 3 studies¹ - 12 DU dose
(incidence > 2% in any treatment group any treatment group)**

| | 18-65 years of age | | | | > 65 years of age | | | |
|--------------------------------------|----------------------------|--------|----------------------|--------|-------------------------|--------|-------------------|--------|
| | MK-8237 12 DU N = 1,277 | | Placebo N = 1,282 | | MK-8237 12 DU N = 11 | | Placebo N = 20 | |
| | n | % | n | % | n | % | n | % |
| Subjects reporting ≥ 1 adverse event | 1,047 | (82.0) | 811 | (63.3) | 10 | (90.9) | 16 | (80.0) |
| Cardiac disorders | 8 | (0.6) | 6 | (0.5) | 1 | (9.1) | 2 | (10.0) |
| Coronary artery disease | 1 | (0.1) | 0 | (0.0) | 1 | (9.1) | 0 | (0.0) |
| Myocardial infarction | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (5.0) |
| Tachycardia | 1 | (0.1) | 1 | (0.1) | 0 | (0.0) | 1 | (5.0) |
| Ear and labyrinth disorders | 376 | (29.4) | 90 | (7.0) | 3 | (27.3) | 1 | (5.0) |
| Ear pruritus | 364 | (28.5) | 83 | (6.5) | 2 | (18.2) | 1 | (5.0) |
| Sudden hearing loss | 0 | (0.0) | 0 | (0.0) | 1 | (9.1) | 0 | (0.0) |
| Eye disorders | 58 | (4.5) | 55 | (4.3) | 2 | (18.2) | 3 | (15.0) |
| Cataract | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (5.0) |
| Eye irritation | 5 | (0.4) | 1 | (0.1) | 1 | (9.1) | 0 | (0.0) |
| Eye pruritus | 26 | (2.0) | 19 | (1.5) | 1 | (9.1) | 2 | (10.0) |

House Dust Mites (Dermatophagoides farinae and Dermatophagoides pteronyssinus) Allergen Extract
(MK-8237) Proposed Trade Name: ODACTRAM

| Table 6b: Adverse events in adults in Phase 2 and Phase 3 studies1 - 12 DU dose (incidence > 2% in any treatment group any treatment group) | | | | | | | | |
|---|-----|--------|-----|--------|---|--------|---|--------|
| Gastrointestinal disorders | 781 | (61.2) | 304 | (23.7) | 7 | (63.6) | 5 | (25.0) |
| Abdominal pain upper | 77 | (6.0) | 33 | (2.6) | 1 | (9.1) | 0 | (0.0) |
| Diarrhoea | 59 | (4.6) | 29 | (2.3) | 1 | (9.1) | 0 | (0.0) |
| Dyspepsia | 34 | (2.7) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Gastrooesophageal reflux disease | 20 | (1.6) | 3 | (0.2) | 0 | (0.0) | 1 | (5.0) |
| Glossodynia | 109 | (8.5) | 23 | (1.8) | 1 | (9.1) | 1 | (5.0) |
| Lip oedema | 27 | (2.1) | 4 | (0.3) | 0 | (0.0) | 0 | (0.0) |
| Lip pain | 1 | (0.1) | 0 | (0.0) | 1 | (0.0) | 0 | (0.0) |
| Lip swelling | 140 | (11.0) | 19 | (1.5) | 3 | (27.3) | 0 | (0.0) |
| Mouth swelling | 74 | (5.8) | 10 | (0.8) | 0 | (0.0) | 0 | (0.0) |
| Mouth ulceration | 73 | (5.7) | 27 | (2.1) | 2 | (18.2) | 0 | (0.0) |
| Nausea | 117 | (9.2) | 51 | (4.0) | 1 | (9.1) | 0 | (0.0) |
| Oedema mouth | 58 | (4.5) | 1 | (0.1) | 1 | (9.1) | 0 | (0.0) |
| Oral pain | 23 | (1.8) | 6 | (0.5) | 0 | (0.0) | 1 | (5.0) |
| Oral pruritus | 522 | (40.9) | 109 | (8.5) | 3 | (27.3) | 3 | (15.0) |
| Palatal swelling | 71 | (5.6) | 9 | (0.7) | 1 | (9.1) | 1 | (5.0) |
| Paraesthesia oral | 101 | (7.9) | 23 | (1.8) | 0 | (0.0) | 0 | (0.0) |
| Stomatitis | 27 | (2.1) | 14 | (1.1) | 0 | (0.0) | 0 | (0.0) |
| Swollen tongue | 117 | (9.2) | 14 | (1.1) | 1 | (9.1) | 1 | (5.0) |
| Tongue pruritus | 64 | (5.0) | 14 | (1.1) | 0 | (0.0) | 0 | (0.0) |
| Tongue ulceration | 80 | (6.3) | 16 | (1.2) | 2 | (18.2) | 2 | (10.0) |
| Vomiting | 31 | (2.4) | 13 | (1.0) | 0 | (0.0) | 0 | (0.0) |
| General disorders & administration site conditions | 78 | (6.1) | 58 | (4.5) | 0 | (0.0) | 3 | (15.0) |
| Asthenia | 3 | (0.2) | 1 | (0.1) | 0 | (0.0) | 1 | (5.0) |
| Chest discomfort | 12 | (0.9) | 7 | (0.5) | 0 | (0.0) | 1 | (5.0) |
| Fatigue | 19 | (1.5) | 12 | (0.9) | 0 | (0.0) | 1 | (5.0) |
| Immune system disorders | 8 | (0.6) | 15 | (1.2) | 0 | (0.0) | 1 | (5.0) |
| Allergy to animal | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (5.0) |
| Infections and infestations | 446 | (34.9) | 432 | (33.7) | 6 | (54.5) | 7 | (35.0) |
| Bronchitis | 42 | (3.3) | 41 | (3.2) | 0 | (0.0) | 0 | (0.0) |
| Conjunctivitis | 3 | (0.2) | 4 | (0.3) | 1 | (9.1) | 0 | (0.0) |
| Diverticulitis | 2 | (0.2) | 1 | (0.1) | 1 | (9.1) | 0 | (0.0) |
| Influenza | 30 | (2.3) | 23 | (1.8) | 0 | (0.0) | 1 | (5.1) |
| Lower respiratory tract infection | 5 | (0.4) | 4 | (0.3) | 0 | (0.0) | 1 | (5.1) |
| Nasopharyngitis | 155 | (12.1) | 152 | (11.9) | 3 | (27.3) | 3 | (15.0) |
| Pharyngitis | 42 | (3.3) | 41 | (3.2) | 0 | (0.0) | 0 | (0.0) |
| Rhinitis | 14 | (1.1) | 8 | (0.6) | 1 | (9.1) | 0 | (0.0) |
| Sinusitis | 39 | (3.1) | 38 | (3.0) | 0 | (0.0) | 0 | (0.0) |
| Upper respiratory tract infection | 88 | (6.9) | 94 | (7.3) | 2 | (18.2) | 3 | (15.0) |
| Urinary tract infection | 8 | (0.6) | 15 | (1.2) | 1 | (9.1) | 0 | (0.0) |
| Vaginal infection | 3 | (0.2) | 2 | (0.2) | 1 | (9.1) | 0 | (0.0) |
| Viral upper respiratory tract infection | 11 | (0.9) | 20 | (1.6) | 0 | (0.0) | 1 | (5.0) |
| Injury, poisoning and procedural complications | 98 | (7.7) | 102 | (8.0) | 1 | (9.1) | 1 | (5.0) |
| Accidental overdose | 40 | (3.1) | 36 | (2.8) | 1 | (9.1) | 1 | (5.0) |
| Procedural pain | 4 | (0.3) | 4 | (0.3) | 0 | (0.0) | 1 | (5.0) |
| Metabolism and nutrition disorders | 13 | (1.0) | 10 | (0.8) | 0 | (0.0) | 1 | (5.0) |
| Dyslipidaemia | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (5.0) |
| Musculoskeletal and connective tissue disorders | 70 | (5.5) | 57 | (4.4) | 1 | (9.1) | 1 | (5.0) |

House Dust Mites (*Dermatophagoides farinae* and *Dermatophagoides pteronyssinus*) Allergen Extract
(MK-8237) Proposed Trade Name: ODACTRAM

| Table 6b: Adverse events in adults in Phase 2 and Phase 3 studies¹ - 12 DU dose (incidence > 2% in any treatment group any treatment group) | | | | | | | | |
|---|-----|--------|-----|--------|---|--------|---|--------|
| Arthralgia | 8 | (0.6) | 8 | (0.6) | 1 | (9.1) | 0 | (0.0) |
| Musculoskeletal pain | 6 | (0.5) | 4 | (0.3) | 1 | (9.1) | 0 | (0.0) |
| Osteoarthritis | 2 | (0.2) | 2 | (0.2) | 0 | (0.0) | 1 | (5.0) |
| Nervous system disorders | 155 | (12.1) | 109 | (8.5) | 2 | (18.2) | 0 | (0.0) |
| Dysgeusia | 69 | (5.4) | 25 | (2.0) | 2 | (18.2) | 0 | (0.0) |
| Headache | 48 | (3.8) | 67 | (5.2) | 0 | (0.0) | 0 | (0.0) |
| Respiratory, thoracic and mediastinal disorders | 640 | (50.1) | 317 | (24.7) | 4 | (36.4) | 7 | (35.0) |
| Asthma | 40 | (3.1) | 44 | (3.4) | 0 | (0.0) | 1 | (5.0) |
| Cough | 32 | (2.5) | 31 | (2.4) | 1 | (9.1) | 2 | (10.0) |
| Dyspnoea | 26 | (2.0) | 25 | (2.0) | 0 | (0.0) | 0 | (0.0) |
| Oropharyngeal pain | 37 | (2.9) | 23 | (1.8) | 0 | (0.0) | 1 | (5.0) |
| Pharyngeal erythema | 17 | (1.3) | 5 | (0.4) | 1 | (9.1) | 0 | (0.0) |
| Pharyngeal inflammation | 1 | (0.1) | 1 | (0.1) | 0 | (0.0) | 1 | (5.0) |
| Pharyngeal oedema | 105 | (8.2) | 15 | (1.2) | 1 | (9.1) | 0 | (0.0) |
| Respiratory tract congestion | 1 | (0.1) | 2 | (0.2) | 0 | (0.0) | 1 | (5.0) |
| Rhinitis allergic | 20 | (1.6) | 29 | (2.3) | 0 | (0.0) | 0 | (0.0) |
| Rhinorrhoea | 9 | (0.7) | 10 | (0.8) | 0 | (0.0) | 1 | (5.0) |
| Throat irritation | 529 | (41.4) | 153 | (11.9) | 4 | (36.4) | 3 | (15.0) |
| Skin and subcutaneous tissue disorders | 88 | (6.9) | 79 | (6.2) | 0 | (0.0) | 4 | (20.0) |
| Hyperhidrosis | 2 | (0.2) | 0 | (0.0) | 0 | (0.0) | 1 | (5.0) |
| Pruritus | 15 | (1.2) | 12 | (0.9) | 0 | (0.0) | 1 | (5.0) |
| Urticaria | 24 | (1.9) | 15 | (1.2) | 0 | (0.0) | 2 | (10.0) |
| ¹ Adult recipients receiving MK-8273 (12 DU dose) in Studies MT-04, P003, MT-06, P001 (the only Phase II-III trials that tested the MK-8237 12 DU dose) Every subject is counted a single time for each applicable row and column. A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding. From STN 125592.0009, Table 2 (selected ISS data restricted to 12 DU dose adult recipients) | | | | | | | | |

Deaths

No cases of deaths or anaphylactic shock were reported within the clinical development program.

Serious adverse events

These included events described as one or more of the following:

Death

Persistent or significant disability/incapacity

Congenital anomaly/birth defect

Associated with an overdose**

Life-threatening

Resulted in or prolonged inpatient hospitalization

Cancer*

Any important medical event

*In Merck-sponsored trials, reports of cancer were classified as serious, whether or not other serious criteria were met.

**In Merck-sponsored trials, reports of adverse events associated with an overdose were classified as serious and reports of overdose without additional adverse events were classified as non-serious events of clinical interest (ECI)

NOTE: These above types of adverse events were not necessarily classified as serious in and of themselves, in ALK-sponsored trials, but were included in the safety data bases for each ALK-sponsored study. (see Table 1, including footnotes for trials listed by sponsor)

Serious adverse events in Phase 1 studies

A single serious adverse event was reported in Phase 1 studies. A child in study MT03 experienced an asthmatic crisis with hospitalization prior to receiving any study treatment. This subject fully recovered and continued on study as planned.

Serious adverse events in Phase 2 and Phase 3 studies

Serious adverse events were reported in 68 subjects: 37 on MK-8237 (17 on 12 DU and 20 on 6 DU) and 31 on placebo in the five Phase 2 and 3 studies.

| Table 7: Summary of all serious adverse events – Phase 2 and/or 3 clinical studies¹ | | | | | | |
|---|--------------------------|----------|-----------------------|----------|----------------------------|----------|
| MedDRA System Organ Class | Dose (MK-8237) | | | | | |
| | 12 DU N=1,383 | | 6 DU N=808 | | Placebo N=1,540 | |
| | n | % | n | % | n | % |
| Subjects reporting any serious adverse event | 15 | (1.1) | 20 | (2.5) | 31 | (2.0) |
| Blood and lymphatic system disorders | 0 | (0.0) | 1 | (0.1) | 0 | (0.0) |
| Cardiac disorders | 1 | (0.1) | 1 | (0.1) | 1 | (0.1) |
| Ear and labyrinth disorders | 2 | (0.1) | 0 | (0.0) | 1 | (0.1) |
| Eye disorders | 0 | (0.0) | 1 | (0.1) | 1 | (0.1) |
| Gastrointestinal disorders | 0 | (0.0) | 2 | (0.2) | 5 | (0.3) |
| Hepatobiliary disorders | 0 | (0.0) | 1 | (0.1) | 2 | (0.1) |
| Immune system disorders | 0 | (0.0) | 0 | (0.0) | 2 | (0.1) |
| Injury, poisoning and procedural complications | 2 | (0.1) | 2 | (0.2) | 6 | (0.4) |
| Musculoskeletal and connective tissue disorders | 1 | (0.1) | 1 | (0.1) | 0 | (0.0) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0 | (0.0) | 0 | (0.0) | 4 | (0.3) |
| Nervous system disorders | 0 | (0.0) | 2 | (0.2) | 2 | (0.1) |
| Pregnancy, puerperium and perinatal conditions | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Psychiatric disorders | 0 | (0.0) | 1 | (0.1) | 3 | (0.2) |
| Renal and urinary disorders | 3 | (0.2) | 1 | (0.1) | 2 | (0.1) |
| Respiratory, thoracic and mediastinal disorders | 3 | (0.2) | 1 | (0.1) | 2 | (0.1) |
| Vascular disorders | 2 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| 1. All randomized subjects except MT-02 where only those randomized to MK-8237 (6 DU) & placebo arms are included. Every subject is counted a single time for each applicable row and column. MedDRA: Medical Dictionary for drug-related adverse events SOC: System Organ Class PT: Preferred Term No treatment group reported >2 subjects for any MedDRA PT, thus none are listed in this table. From STN 125592.0, Section 5.3.5.3.3, Table 35 | | | | | | |

Serious adverse events not meeting the ICH definition of seriousness

Merck trial protocol guidance for reporting of overdoses required that any adverse events temporally associated with the overdose itself were to be reported as serious, whether or not they met the ICH definition of serious. Three such adverse events (in 2 subjects treated with MK8237 12 DU) were reported as summarized in the following table. Note that these adverse events are not included in evaluations or tabulations of the safety database serious adverse events.

**Table 8: Protocol-defined serious adverse events not meeting ICH criteria
Phase 2 and/or Phase 3 studies¹**

| MedDRA System Organ Class Preferred Term | Dose (MK-8237) | | | | | |
|--|------------------|-------|---------------|-------|--------------------|-------|
| | 12 DU N=1,383 | | 6 DU N=808 | | Placebo N=1,540 | |
| | n | % | n | % | n | % |
| Subjects with ≥ 1 event | 2 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Gastrointestinal disorders | 2 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Oral pain | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Oral pruritus | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Respiratory, thoracic and mediastinal disorders | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Throat irritation | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| 1. All randomized subjects except MT-02 where only those randomized to MK-8237 (6 DU) and placebo are included. Every subject is counted a single time for each applicable row and column. From STN 125592, Module 5.3.6.3.3, Table 39 | | | | | | |

Adverse events upgraded to serious after database lock

The classification of two adverse events was upgraded to serious after database lock, one each in the MT-04 and MT-06 trials; these events were not included in the pooled database or in the serious adverse event tables and listings. In the MT-04 trial, the serious adverse event reported post-database lock was placenta praevia hemorrhage in a placebo recipient; in the MT-06 trial, the serious adverse event reported post-database lock was idiopathic thrombocytopenic purpura in a subject in the MK-8237 6 DU treatment group.

Life-threatening adverse events

No SAEs in the clinical development program were considered life-threatening

Serious adverse events considered related to study drug

5 subjects experienced SAEs deemed by the manufacturer as related to study drug in the clinical development program - all occurring in the MT-04 trial. In the 12 DU group, one subject experienced moderate worsening of asthma; in the 6 DU group, 1 subject experienced mild arthralgia and 1 subject experienced moderate laryngeal oedema; and in the placebo group, 1 subject experienced hepatocellular injury and 1 subject experienced erosive oesophagitis.

Discontinuations

The most common types of adverse events leading to discontinuation included local application site, skin, gastrointestinal and respiratory systems, which appeared highest in the MK-8237 (12 DU) arm as compared to placebo, with rates in the MK-8237 (6 DU) arm generally falling in between the other two groups.

| Table 9: Discontinuations due to adverse events - Phase 2 and Phase 3¹ (all SOC, PT with n > 2 any treatment group) | | | | | | |
|---|-----------------------|----------|----------------------|----------|----------------|----------|
| | MK-8237: 12 DU | | MK-8237: 6 DU | | Placebo | |
| | n | % | n | % | n | % |
| Subjects in population | 1383 | (100) | 808 | (100) | 1540 | (100) |
| With ≥1 adverse event leading to discontinuation | 113 | (8.2) | 26 | (3.2) | 41 | (2.7) |
| Cardiac Disorders | 1 | (0.1) | 2 | (0.2) | 1 | (0.1) |
| Ear And Labyrinth Disorders | 15 | (1.1) | 0 | (0.0) | 1 | (0.1) |
| Ear Pruritus | 15 | (1.1) | 0 | (0.0) | 0 | (0.0) |
| Endocrine disorders | 0 | (0.0) | 0 | (0.0) | 1 | (0.1) |
| Eye Disorders | 2 | (0.1) | 1 | (0.1) | 1 | (0.1) |
| Gastrointestinal Disorders | 73 | (5.3) | 14 | (1.4) | 5 | (0.3) |
| Abdominal pain upper | 5 | (0.4) | 2 | (0.2) | 1 | (0.1) |
| Diarrhoea | 4 | (0.3) | 0 | (0.0) | 1 | (0.1) |
| Dyspepsia | 4 | (0.3) | 1 | (0.1) | 0 | (0.0) |
| Dysphagia | 4 | (0.3) | 1 | (0.1) | 0 | (0.0) |
| Glossodynia | 7 | (0.5) | 0 | (0.0) | 0 | (0.0) |
| Lip swelling | 9 | (0.7) | 1 | (0.1) | 0 | (0.0) |
| Mouth swelling | 15 | (1.1) | 0 | (0.0) | 0 | (0.0) |
| Mouth ulceration | 7 | (0.5) | 0 | (0.0) | 1 | (0.0) |
| Nausea | 13 | (0.9) | 0 | (0.0) | 0 | (0.0) |
| Oedema mouth | 7 | (0.5) | 3 | (0.4) | 0 | (0.0) |
| Oral pain | 3 | (0.2) | 0 | (0.0) | 0 | (0.0) |
| Oral pruritus | 17 | (1.2) | 4 | (0.5) | 0 | (0.0) |
| Palatal swelling | 7 | (0.5) | 0 | (0.0) | 0 | (0.0) |
| Paraesthesia oral | 3 | (0.2) | 0 | (0.0) | 0 | (0.0) |
| Swollen tongue | 14 | (1.1) | 1 | (0.1) | 0 | (0.0) |
| Tongue oedema | 6 | (0.4) | 0 | (0.0) | 0 | (0.0) |
| General disorders & administration site conditions | 3 | (0.2) | 3 | (0.4) | 1 | (0.1) |
| Hepatobiliary disorders | 0 | (0.0) | 1 | (0.1) | 0 | (0.0) |
| Immune system disorders | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Infections and infestations | 7 | (0.5) | 3 | (0.4) | 5 | (0.3) |
| Injury, poisoning & procedural complications | 0 | (0.0) | 0 | (0.0) | 1 | (0.1) |
| Musculoskeletal and connective tissue disorders | 1 | (0.1) | 0 | (0.0) | 1 | (0.1) |
| Neoplasms benign, malignant and unspecified (incl cysts & polyps) | 0 | (0.1) | 0 | (0.0) | 1 | (0.1) |
| Nervous system disorders | 5 | (0.4) | 1 | (0.1) | 4 | (0.3) |
| Pregnancy, puerperium and perinatal conditions | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Psychiatric disorders | 1 | (0.1) | 1 | (0.1) | 4 | (0.3) |
| Renal and urinary disorders | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Reproductive system and breast disorders | 0 | (0.0) | 1 | (0.1) | 0 | (0.0) |
| Respiratory, thoracic & mediastinal disorders | 46 | (3.3) | 8 | (1.0) | 12 | (0.8) |
| Asthma | 7 | (0.5) | 3 | (0.4) | 5 | (0.3) |
| Dyspnoea | 6 | (0.4) | 2 | (0.2) | 5 | (0.3) |
| Pharyngeal oedema | 6 | (0.4) | 0 | (0.0) | 0 | (0.0) |
| Throat irritation | 23 | (1.7) | 2 | (0.2) | 0 | (0.0) |
| Skin and subcutaneous tissue disorders | 13 | (0.9) | 1 | (0.1) | 8 | (0.5) |
| Pruritus | 3 | (0.2) | 0 | (0.0) | 0 | (0.0) |
| Rash | 3 | (0.2) | 0 | (0.0) | 1 | (0.1) |
| Urticaria | 6 | (0.4) | 0 | (0.0) | 4 | (0.3) |
| Vascular disorders | 0 | (0.0) | 0 | (0.0) | 1 | (0.1) |
| 1. All randomized subjects except MT-02 where only those randomized to MK-8237 (6 DU) and placebo are included SOC: Medical Dictionary for drug-related adverse events (MedDRA) System Organ Class; PT: MedDRA Preferred Term From STN 125592.0 Module 5.3.5.3.3 Table 27 | | | | | | |

House Dust Mites (*Dermatophagoides farinae* and *Dermatophagoides pteronyssinus*) Allergen Extract (MK-8237) Proposed Trade Name: ODACTRAM

Treatment interruptions

Treatment interruptions were highest in the MK-8237 (12 DU) treatment arm, and similar in the MK-8237 (6 DU) and placebo arms. Of note, discontinuations from the study after treatment interruptions due to AEs were notably higher in the 12 DU group (14.5% of all interruptions) as compared to the 6 DU group (3.4% of all interruptions) and placebo group (3.8% of all interruptions).

| Table 10: Treatment interruption - Phase 2 and Phase 3 studies¹ | | | | | | |
|--|------------------------|----------|-----------------------|----------|----------------|----------|
| | MK-8237 (12 DU) | | MK-8237 (6 DU) | | Placebo | |
| | N = 138 | | N = 89 | | N = 80 | |
| | n | % | n | % | n | % |
| Completed despite interruption | 109 | (79.0) | 75 | (84.3) | 67 | (83.8) |
| Discontinued after interruption | 29 | (21.0) | 14 | (15.7) | 13 | (16.3) |
| Due to adverse event | 20 | (14.5) | 3 | (3.4) | 3 | (3.8) |
| Due to being lost to follow-up | 1 | (0.7) | 0 | (0.0) | 0 | (0.0) |
| Due to other reason | 3 | (2.2) | 5 | (5.6) | 2 | (2.5) |
| Due to protocol violation | 0 | (0.0) | 5 | (5.6) | 2 | (2.5) |
| Due to withdrawal by subject | 5 | (3.6) | 1 | (1.1) | 6 | (7.5) |
| 1. All randomized subjects except MT-02 where only those randomized to MK-8237 (6 DU) & placebo are included. Subject classified by last recorded disposition Percentages based upon subjects randomized and the subset whose treatment was interrupted in a treatment group From STN 125592.0, Module 2.5, Table 12, Module 5.3.5.3.3, Table 9 | | | | | | |

The manufacturer notes that the rate of adverse events leading to treatment interruption and related to local application site reactions, i.e., within the Gastrointestinal Disorders System Organ Class and/or involving the mouth, throat or ear, tended to be higher in the 12 DU group with some dose-response trends as shown in the following table.

This reviewer agrees that there is evidence of a dose-response effect for events classified under the System Organ Class of Gastrointestinal Disorders for the Preferred Terms: Glossodynia, Lip swelling, Mouth Swelling, Mouth ulceration, Nausea, Oral pruritus, Stomatitis, Swollen tongue, Tongue ulceration, Toothache and Vomiting, and under the System Organ Class of Respiratory, Thoracic & Mediastinal Disorders for the Preferred Terms: Cough, Oropharyngeal pain, Pharyngeal oedema and Throat irritation.

| Table 11: Adverse events leading to treatment interruptions - Phase 2 and Phase 3 studies¹ | | | | | | |
|--|-----------------------|----------|----------------------|----------|----------------|----------|
| All events by SOC and for any PT with n > 2 in any of the treatment groups | | | | | | |
| | MK-8237: 12 DU | | MK-8237: 6 DU | | Placebo | |
| | 1383 | | 808 | | 1540 | |
| Subjects in population | n | % | n | % | n | % |
| With one or more AE leading to treatment interruption | 138 | (10.0) | 89 | (11.0) | 307 | (8.2) |
| Blood and lymphatic disorders | 0 | (0.0) | 0 | (0.0) | 2 | (0.1) |
| Cardiac disorders | 0 | (0.0) | 1 | (0.1) | 1 | (0.1) |
| Ear and labyrinth disorders | 6 | (0.4) | 0 | (0.0) | 1 | (0.1) |
| Ear pruritus | 6 | (0.4) | 0 | (0.0) | 1 | (0.1) |
| Eye Disorders | 1 | (0.1) | 2 | (0.2) | 2 | (0.1) |
| Gastrointestinal Disorders | 50 | (3.6) | 20 | (2.5) | 16 | (1.0) |
| Diarrhoea | 3 | (0.2) | 2 | (0.2) | 2 | (0.1) |
| Glossodynia | 3 | (0.2) | 1 | (0.1) | 1 | (0.1) |
| Lip swelling | 5 | (0.4) | 0 | (0.0) | 0 | (0.0) |
| Mouth swelling | 7 | (0.5) | 0 | (0.0) | 0 | (0.0) |

| Table 11: Adverse events leading to treatment interruptions - Phase 2 and Phase 3 studies¹ | | | | | | |
|---|----|-------|----|-------|----|-------|
| All events by SOC and for any PT with n > 2 in any of the treatment groups | | | | | | |
| Mouth ulceration | 3 | (0.2) | 0 | (0.0) | 2 | (0.1) |
| Nausea | 2 | (0.1) | 0 | (0.0) | 3 | (0.2) |
| Oral pruritus | 9 | (0.7) | 3 | (0.4) | 1 | (0.1) |
| Stomatitis | 3 | (0.2) | 1 | (0.1) | 1 | (0.1) |
| Swollen tongue | 4 | (0.4) | 1 | (0.1) | 0 | (0.0) |
| Tongue ulceration | 3 | (0.2) | 0 | (0.0) | 3 | (0.2) |
| Toothache | 4 | (0.4) | 1 | (0.1) | 0 | (0.0) |
| Vomiting | 3 | (0.2) | 1 | (0.1) | 1 | (0.1) |
| General disorders & administration site conditions | 3 | (0.2) | 2 | (0.2) | 1 | (0.1) |
| Immune system disorders | 0 | (0.0) | 1 | (0.1) | 0 | (0.0) |
| Infections and infestations | 68 | (4.9) | 60 | (7.4) | 48 | (3.1) |
| Acute tonsillitis | 6 | (0.4) | 4 | (0.5) | 1 | (0.1) |
| Bronchitis | 4 | (0.3) | 5 | (0.6) | 6 | (0.4) |
| Gastroenteritis | 2 | (0.1) | 1 | (0.1) | 4 | (0.3) |
| Influenza | 5 | (0.4) | 5 | (0.6) | 2 | (0.1) |
| Nasopharyngitis | 16 | (1.2) | 15 | (1.9) | 15 | (1.0) |
| Pharyngitis | 13 | (0.9) | 8 | (1.0) | 6 | (0.4) |
| Respiratory tract infection | 3 | (0.2) | 4 | (0.5) | 1 | (0.1) |
| Upper respiratory tract infection | 8 | (0.6) | 7 | (0.9) | 8 | (0.5) |
| Viral infection | 2 | (0.1) | 4 | (0.3) | 3 | (0.2) |
| Injury, poisoning & procedural complications | 8 | (0.6) | 0 | (0.0) | 2 | (0.1) |
| Investigations | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Metabolism and nutrition disorders | 1 | (0.1) | 0 | (0.0) | 1 | (0.1) |
| Musculoskeletal and connective tissue disorders | 2 | (0.1) | 0 | (0.0) | 1 | (0.1) |
| Neoplasms benign, malignant and unspecified (incl cysts & polyps) | 2 | (0.1) | 0 | (0.0) | 1 | (0.1) |
| Nervous system disorders | 4 | (0.4) | 0 | (0.0) | 4 | (0.4) |
| Reproductive system and breast disorders | 0 | (0.0) | 1 | (0.1) | 0 | (0.0) |
| Respiratory, thoracic & mediastinal disorders | 26 | (1.9) | 16 | (2.0) | 10 | (0.6) |
| Asthma | 6 | (0.4) | 7 | (0.9) | 3 | (0.2) |
| Cough | 3 | (0.2) | 0 | (0.0) | 0 | (0.0) |
| Oropharyngeal pain | 4 | (0.4) | 2 | (0.2) | 1 | (0.1) |
| Pharyngeal oedema | 4 | (0.4) | 0 | (0.0) | 1 | (0.1) |
| Throat irritation | 6 | (0.4) | 2 | (0.2) | 1 | (0.1) |
| Skin and subcutaneous tissue disorders | 7 | (0.5) | 2 | (0.2) | 4 | (0.4) |
| Urticaria | 3 | (0.2) | 0 | (0.0) | 3 | (0.2) |
| Surgical and medical procedures | 2 | (0.1) | 0 | (0.0) | 2 | (0.1) |
| Vascular disorders | 0 | (0.0) | 0 | (0.0) | 1 | (0.1) |
| 1. All randomized subjects except MT-02 where only those randomized to MK-8237 (6 DU) and placebo arms are included. SOC: Medical Dictionary for drug-related adverse events (MedDRA) System Organ Class; PT: MedDRA Preferred Term From STN 125592.0 Module 5.3.5.3.3 Table 46 | | | | | | |

Events of clinical interest (ECIs)

ECIs were evaluated in all of the trials in the clinical development program. Merck-sponsored studies prospectively monitored for ECIs, while data from ALK- sponsored studies were evaluated for ECIs *post hoc*.

The ECIs included the following:

- Drug-induced liver injury (DILI)
AST or ALT laboratory value greater than or equal to 3X the upper limit of normal and an elevated total bilirubin laboratory value greater than or equal to 2X the upper limit of normal.

House Dust Mites (*Dermatophagoides farinae* and *Dermatophagoides pteronyssinus*) Allergen Extract (MK-8237) Proposed Trade Name: ODACTRAM

NOTE: DILI was not identified as an ECI in the Phase I-III trials sponsored by ALK (MT-01, MT-03, MT-02, MT-04, and MT-06).

- **Overdose**
Use above prescribed dose without additional associated adverse events, including any clinical and laboratory abnormalities. Overdose events were classified as serious for the purposes of monitoring and follow-up, but unless another event associated with the overdose was itself classified as serious, the overdose itself was not reported or analyzed as an SAE in the clinical study report.
- **Anaphylactic reactions, anaphylaxis and/or systemic allergic reactions***
*Determined by investigators and guided by the recommendations in the Food Allergy & Anaphylaxis Network (FAAN) Report which proposed clinical criteria that would increase diagnostic precision in anaphylaxis (Sampson 2005; Sampson 2006).
- **Events treated with epinephrine**
- **Severe local swelling or edema of the mouth and/or throat**

| Table 12: Summary of events of clinical interest (ECI)^{1,2} | | | | | | |
|--|-----------------------------------|----------|---------------------------------|----------|-----------------------------|----------|
| | MK-8237 12 DU N = 1383 | | MK-8237 6 DU N = 808 | | Placebo N = 1540 | |
| | n | % | n | % | n | % |
| Subjects with ≥1 event of clinical interest | 56 | (4.0) | 6 | (0.7) | 47 | (3.1) |
| Drug-induced liver injury (DILI) ³ | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Overdose ⁴ | 45 | (3.3) | 6 | (0.7) | 43 | (2.8) |
| Systemic allergic reactions (anaphylactic / hypersensitivity reactions) ⁵ | 4 | (0.3) | 0 | (0.0) | 3 | (0.2) |
| Adverse events treated with epinephrine | 5 | (0.4) | 0 | (0.0) | 3 | (0.2) |
| Severe local swelling or oedema of the mouth and/or throat | 5 | (0.4) | 0 | (0.0) | 0 | (0.0) |
| 1. All randomized subjects except MT-02 where only those randomized to MK-8237 (6 DU) and placebo are included. 2. These ECIs were prospectively defined and monitored only in Merck sponsored trials (P001, P003, P008); but were evaluated retrospectively in the ALK sponsored studies. 3. AST or ALT laboratory value ≥ 3X the upper limit of normal and total bilirubin laboratory value ≥ 2X the upper limit of normal and, at the same time, an alkaline phosphatase laboratory value < 2X the upper limit of normal (protocol-specified or unscheduled laboratory testing). 4. Use above prescribed dose without additional associated adverse events. 5. Systemic allergic reactions as determined by investigators Every subject counted once for each applicable row and column From STN 125592, Module 5.3.5.3.3, Table 57; Module 2.7.4, page 169-170 and Table 51. | | | | | | |

Drug-induced liver injury (DILI)

Drug Induced Liver Injury (DILI) was identified as an ECI for the Phase 1-3 trials conducted by Merck (P008, P003 and P001). The DILI definition was based on criteria defined in regulatory guidance documents; the purpose of the criteria is to specify a threshold of abnormal hepatic tests that may require an additional evaluation for an underlying etiology. The criteria for DILI are as follows:

AST or ALT laboratory value ≥ 3X the upper limit of normal and a total bilirubin laboratory value ≥ 2X the upper limit of normal and, at the same time, an alkaline phosphatase laboratory value ≤ 2X the upper limit of normal, as determined by way of protocol-specified laboratory testing or unscheduled laboratory testing.

House Dust Mites (*Dermatophagoides farinae* and *Dermatophagoides pteronyssinus*) Allergen Extract (MK-8237) Proposed Trade Name: ODACTRAM

No subject met these DILI criteria in any of the 3 Merck trials (P008, P003, P001).

While DILI was not identified as an ECI in the Phase I-III trials sponsored by ALK (MT-01, MT-03, MT-02, MT-04, and MT-06), overall, few liver-related adverse events were reported in the MK-8237 clinical development program. The manufacturer reports they found no evidence of any association between MK-8237 and hepatic injury (manufacturer's analyses not provided).

Overdose

Two subjects, both in the 12 DU group, had accidental overdoses (total daily dose of 24 DU) and subsequent development of mild adverse events (oral pruritus and throat irritation in one subject and oral pain in the other subject). In the Merck-sponsored trials, reports of adverse events associated with an overdose were classified as serious for safety monitoring; reports of overdose without additional adverse events were classified as non-serious events of clinical interest (ECI). The adverse events reported for the two subjects identified as having had an accidental overdose did not meet International Conference on Harmonisation (ICH) criteria for seriousness and are not included in evaluations of serious adverse events. The adverse events for both subjects were assessed as drug-related by the investigator.

Systemic allergic reactions

Phase 1 systemic allergic reactions

No systemic allergic reactions were reported in Phase 1 trials.

Phase 2 systemic allergic reactions

Seven subjects experienced a systemic allergic reaction in Phase 2 and Phase 3 studies: four in the 12 DU treatment group and 3 in the placebo group, summarized in the following table. Only a single reaction, in the 12 DU treatment group, was considered related to treatment by the investigator.

| Table 13: Systemic Allergic Reactions ¹ in Phase 2 and Phase 3 Trials ² | | | | | | | | |
|---|--------------|-------------|--------------------------------|-----------------------|---------|--------------|----------|-------------------|
| Study | Demographics | Onset (Day) | Last recorded study drug (day) | Adverse Event | Serious | Action Taken | Outcome | Suspected trigger |
| Active treatment: MK-8237 12 DU | | | | | | | | |
| 001 | 16 y W M | 18 | 16 | Anaphylactic reaction | N | N/A | Resolved | Food |
| 001 | 47 y W F | 245 | 309 | Hypersensitivity | N | None | Unknown | Dust |
| 001 | 34 y W F | 1 | 1 | Hypersensitivity | N | Discontinued | Resolved | MK-8237 |
| 014 | 48 y W F | 392 | 456 | Drug hypersensitivity | N | Non | Resolved | Amoxicillin |
| Placebo | | | | | | | | |
| 001 | 23 y W M | 147 | 207 | Drug hypersensitivity | N | None | Resolved | Bactrim |
| 001 | 38 y W F | 7 | 4 | Anaphylactic reaction | N | None | Resolved | Unidentified |
| 001 | 29 y AA F | 26 | 25 | Anaphylactic reaction | Y | None | Resolved | Food |
| 1. As Determined by Investigator 2. All randomized subjects except MT-02 where only those randomized to MK-8237 (6 DU) and placebo are included From 125592.0, Module 2.5, Table 15 | | | | | | | | |

Systemic allergic reactions - modified Sampson criteria – Phase 2 and 3 studies

Phase 2 and Phase 3 clinical trial data were also evaluated using the modified Sampson criteria, which requires subjects to have at least 2 adverse events affecting at least 2 organ systems.

Only two subjects met the modified Sampson criteria for a systemic allergic reaction:

A subject in the 12 DU group experienced urticaria and oropharyngeal swelling on Day 1, and chest tightness and dyspnea, on 3 separate occasions, Days 2, 3 and 6. All events were classified as mild in severity and resolved without treatment. The subject discontinued on Day 57 due to mouth ulceration (sublingual ulcer reported by patient). None of these events, in any combination, were classified as anaphylaxis by the sponsor.

A subject in the placebo group experienced generalized pruritus and dyspnea on Day 28 resolved within 1 day; lip, ear and oral pruritus together with dyspnea on Days 29, 47-51, 59, 64-66, 69, 70 and 74-76; mild wheezing on Days 61-63; facial pruritus and dyspnea on Days 216-248. All events resolved without treatment and the subject completed the study. None of these events, in any combination, were classified as anaphylaxis by the sponsor.

Use of epinephrine

Adverse events treated with epinephrine in Phase 2 and Phase 3 studies are summarized in the following table. Notably, North American study subjects were provided self-injectable epinephrine and instructed that it be used for significant systemic allergic reactions, which were attributed to the study drug. Self-injectable epinephrine was not provided to subjects enrolled in studies conducted outside the US.

| Table 14: Overview of adverse events treated with epinephrine – Phase 2 and Phase 3 studies^{1,2} | | | | | | |
|--|-----------------------------------|----------|---------------------------------|----------|-----------------------------|----------|
| | MK-8237 12 DU N = 1383 | | MK-8237 6 DU N = 808 | | Placebo N = 1540 | |
| | n | % | n | % | n | % |
| One or more adverse events (PT) treated with epinephrine | 5 | (0.4) | 0 | (0.0) | 3 | (0.2) |
| Oedema mouth | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Chest discomfort | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Anaphylactic reaction | 0 | (0.0) | 0 | (0.0) | 2 | (0.1) |
| Food allergy | 0 | (0.0) | 0 | (0.0) | 1 | (0.1) |
| Hypersensitivity | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Dyspnoea | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Laryngeal oedema | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Oropharyngeal discomfort | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Pharyngeal oedema | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Throat tightness | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| 1. All randomized subjects except MT-02 where only those randomized to MK-8237 (6 DU) and placebo are included | | | | | | |
| 2. A given subject may have >1 associated PT (MedDRA Preferred Term) | | | | | | |
| From STN 125592.0, Module 5.3.5.3.3, Table 59 | | | | | | |

Adverse events treated with epinephrine were attributed to study drug in three subjects (12 DU group); dust allergy in one subject (12 DU group), food allergy in two subjects (placebo group), and undetermined in one subject (placebo group).

House Dust Mites (*Dermatophagoides farinae* and *Dermatophagoides pteronyssinus*) Allergen Extract
(MK-8237) Proposed Trade Name: ODACTRAM

| Table 15: Subjects with treated with epinephrine in Phase 2 and Phase 3^{1,2} | | | | | |
|---|-----------------------|---|-----------------|--|----------------------|
| Subject ID | AE Onset (day) | Adverse Event | Serious? | Treatment² | Discontinued? |
| Active treatment: MK-8237 12 DU | | | | | |
| 120368 | 128 | Chest discomfort | No | Epinephrine (self-administered) | No |
| | | Oropharyngeal discomfort | No | | |
| 120147 | 7 | Body temperature increased ³ | No | Epinephrine (self-administered) Diphenhydramine hydrochloride Prednisone | Yes |
| | | Dyspnoea ³ | No | | |
| | | Gastroenteritis ³ | No | | |
| | | Glossodynia ³ | No | | |
| | | Oedema mouth ³ | No | | |
| | | Throat tightness ³ | No | | |
| 220835 | 12 | Pharyngeal oedema ⁴ | No | Epinephrine (self-administered) Diphenhydramine hydrochloride Fexofenadine hydrochloride | No |
| | | Throat irritation ⁴ | No | | |
| 220529 | 1 | Hypersensitivity ³ | No | Epinephrine, Pseudoephedrine Desloratadine | Yes |
| 1705 | 1 | Laryngeal oedema ³ | No | Epinephrine Desloratadine Methylprednisolone | No |
| Placebo | | | | | |
| 120354 | 234 | Food allergy ⁵ | Yes | Epinephrine (self-administered) | No |
| 120098 | 7 | Anaphylactic reaction ⁶ | No | Epinephrine Fexofenadine hydrochloride Diphenhydramine hydrochloride Famotidine Prednisone Montelukast sodium | No |
| | | Tremor ⁶ | No | | |
| 220571 | 26 | Anaphylactic reaction ⁵ | Yes | Epinephrine (self-administered) | No |
| 1. All randomized subjects except MT-02 where only those randomized to MK-8237 (6 DU) and placebo are included. 2. North American study sites provided epinephrine for self-administration; if self-administered, it is indicated under treatment 3. Attributed to MK-8237; 4. Attributed to dust allergy; 5. Attributed to food allergy; 6. Attributed to unknown cause From 125592.0, Module 2.5, Table 17 | | | | | |

Local allergic reactions

Local reactions tended to occur early in the course of treatment with median onset in the MK-8237 group between 1 and 7 days after treatment initiation, and were typically transient (median duration 13.5 to 60 minutes after the first dose). The most common local reactions (occurring in > 15% of subjects) were compared in the 12 DU treatment group and the placebo group in the table below.

| Table 16: Timing of the most commonly¹ reported local reactions - Phase 2 and Phase 3² studies^{1,2} | | | | | | |
|---|-------------------------------|---|-----------------------------------|------------------------------|---|-----------------------------------|
| | MK-8237 12 DU (N=1383) | | | Placebo (N=1540) | | |
| | Median | | | Median | | |
| | Onset[†] (n) | Duration - Day 1[‡] (n) | Recurrence[§] (n) | Onset[†] (n) | Duration - Day 1[‡] (n) | Recurrence[§] (n) |
| Ear pruritus | 1 day (413) | 30 minutes (289) | 10 days (411) | 4 days (95) | 60 minutes (30) | 3 days (93) |
| Oral pruritus | 1 day (594) | 30 minutes (414) | 12 days (588) | 2 days (131) | 60 minutes (62) | 3 days (128) |
| Throat irritation | 1 day (603) | 42 minutes (460) | 12 days (596) | 2 days (192) | 45 minutes (94) | 3 days (189) |
| 1. >15% of subjects 2. All randomized subjects except MT-02 where only those randomized to MK-8237 (6 DU) and placebo are included [†] Onset reflects the time (in days) that an adverse event was first experienced after treatment initiation. [‡] Duration reflects the length of time (in minutes) that an adverse event lasted after the first dose administered on Day 1. [§] Recurrence reflects occurrence of adverse event measured over the course of consecutive days. From STN 125592.0, Module 2.5, Table 14 | | | | | | |

No reported local allergic swelling resulted in respiratory distress or airway compromise were reported in the Phase 1 studies, but two subjects experienced three events of severe mouth edema in the 16 DU group, a dose higher than the dose subsequently chosen to be evaluated for licensure.

A dose-response was noted with respect to local application site reactions in the Phase 2 and Phase 3 studies as illustrated in the table immediately below.

A single report of local allergic swelling was classified as a serious adverse event in a subject in the 6 DU treatment group with a history of asthma and allergic rhinitis, who experienced laryngeal oedema on Day 176. Direct laryngoscopy revealed edema of the left arytenoid, and no edema of the epiglottis or oropharynx. Study drug was interrupted for eight days and after treatment and resolution of symptoms, study drug was re-initiated and the subject completed the trial.

| Table 17: Pre-specified local reactions - Phase 2 and Phase 3 studies¹ | | | | | | |
|---|-------------------------|----------|-----------------------|----------|---------------------------|----------|
| MedDRA Preferred Term | Dose (MK-8237) | | | | | |
| | 12 DU N=1383 | | 6 DU N=808 | | Placebo N=1540 | |
| | n | % | n | % | n | % |
| With any local application site reaction | 871 | (63.0) | 277 | (34.3) | 293 | (19.0) |
| Ear pruritus | 413 | (29.9) | 33 | (4.1) | 95 | (6.2) |
| Laryngeal oedema | 1 | (0.1) | 1 | (0.1) | 0 | (0.0) |
| Lip oedema | 28 | (2.0) | 9 | (1.1) | 4 | (0.3) |
| Lip swelling | 161 | (11.6) | 14 | (1.7) | 20 | (1.3) |
| Mouth swelling | 83 | (6.0) | 10 | (1.2) | 12 | (0.8) |
| Oedema mouth | 59 | (4.3) | 61 | (7.5) | 1 | (0.1) |
| Oral pruritus | 594 | (43.0) | 136 | (16.8) | 131 | (8.5) |
| Oropharyngeal swelling | 3 | (0.2) | 3 | (0.4) | 1 | (0.1) |
| Palatal oedema | 10 | (0.7) | 2 | (0.2) | 0 | (0.0) |
| Palatal swelling | 82 | (5.9) | 0 | (0.0) | 11 | (0.7) |
| Pharyngeal oedema | 123 | (8.9) | 11 | (1.4) | 23 | (1.5) |
| Throat tightness | 7 | (0.5) | 1 | (0.1) | 3 | (0.2) |
| Swollen tongue | 137 | (9.9) | 8 | (1.0) | 18 | (1.2) |
| Tongue oedema | 23 | (1.7) | 4 | (0.5) | 1 | (0.1) |
| Throat irritation | 603 | (43.6) | 91 | (11.3) | 192 | (12.5) |
| Tongue pruritus | 67 | (4.8) | 33 | (4.1) | 14 | (0.9) |
| 1. All randomized subjects except MT-02 where only subjects randomized to MK-8237(6 DU) & placebo are included. Every subject is counted a single time for each applicable row and column. From STN 125592.0, Module 5.3.5.3.3, Table 40 | | | | | | |

In the combined Phase 2 and Phase 3 trials, the majority of subjects treated with MK-8237 experienced local adverse events of mild or moderate in intensity. A dose-response can be seen for local reactions overall, as summarized in the table immediately above, and by each level of intensity of those local reactions classified as moderate or severe as summarized in the table below. The two most frequently reported local reactions classified as severe were throat irritation occurring in 5 subjects (all in the 12 DU group) and oral pruritus occurring in 6 subjects (5 in the 12 DU group and 1 in 6 DU group).

| Table 18: Local reactions classified as moderate or severe – Phase 2 & Phase 3 ² | | | | | | | | |
|--|------------------------|-----------|---------------------------|--------|-------------------------|-------|---------------------|-------|
| System Organ Class Preferred Term | | Intensity | MK-8237 12 DU N = 1383 | | MK-8237 6 DU N = 808 | | Placebo N = 1540 | |
| | | | n | % | n | % | n | % |
| With ≥ 1 local reaction | | Moderate | 150 | (10.8) | 34 | (4.2) | 18 | (1.2) |
| | | Severe | 15 | (1.1) | 2 | (0.2) | 0 | (0.0) |
| Ear and labyrinth disorders | | Moderate | 50 | (3.6) | 3 | (0.4) | 9 | (0.6) |
| | | Severe | 2 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| | Ear pruritus | Moderate | 50 | (3.6) | 3 | (0.4) | 9 | (0.6) |
| | | Severe | 2 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Gastrointestinal disorders | | Moderate | 126 | (9.1) | 26 | (3.2) | 8 | (0.5) |
| | | Severe | 9 | (0.7) | 2 | (0.2) | 0 | (0.0) |
| | Lip edema | Moderate | 7 | (0.5) | 1 | (0.1) | 1 | (0.1) |
| | | Severe | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| | Lip swelling | Moderate | 26 | (1.9) | 1 | (0.1) | 2 | (0.1) |
| | | Severe | 0 | (0.0) | 1 | (0.1) | 0 | (0.1) |
| | Mouth swelling | Moderate | 25 | (1.8) | 0 | (0.0) | 0 | (0.0) |
| | | Severe | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| | Oedema mouth | Moderate | 14 | (1.9) | 7 | (0.9) | 0 | (0.0) |
| | | Severe | 2 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| | Oral pruritus | Moderate | 70 | (5.1) | 14 | (1.7) | 5 | (0.3) |
| | | Severe | 5 | (0.4) | 1 | (0.1) | 0 | (0.0) |
| | Palatal oedema | Moderate | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| | | Severe | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| | Palatal swelling | Moderate | 18 | (1.3) | 0 | (0.0) | 0 | (0.0) |
| | | Severe | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| | Swollen tongue | Moderate | 23 | (1.7) | 4 | (0.5) | 2 | (0.1) |
| | | Severe | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| | Tongue oedema | Moderate | 8 | (0.6) | 2 | (0.2) | 0 | (0.0) |
| | | Severe | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| | Tongue pruritus | Moderate | 8 | (0.6) | 1 | (0.1) | 1 | (0.1) |
| | | Severe | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Respiratory, mediastinal & thoracic disorders | | Moderate | 83 | (6.0) | 11 | (1.4) | 7 | (1.1) |
| | | Severe | 7 | (0.5) | 0 | (0.0) | 0 | (0.0) |
| | Laryngeal oedema | Moderate | 0 | (0.0) | 1 | (0.1) | 0 | (0.0) |
| | | Severe | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| | Oropharyngeal swelling | Moderate | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| | | Severe | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| | Pharyngeal oedema | Moderate | 26 | (1.9) | 3 | (0.4) | 2 | (0.1) |
| | | Severe | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| | Throat irritation | Moderate | 73 | (5.3) | 8 | (1.0) | 6 | (0.4) |
| | | Severe | 5 | (0.4) | 0 | (0.0) | 0 | (0.0) |
| | Throat tightness | Moderate | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| | | Severe | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| 1. All randomized subjects except MT-02 where only those randomized to MK-8237 (6 DU) & placebo are included Each subject counted once for a specific adverse event, classified according to highest intensity grade indicated. From STN 125592.0, Section 5.3.5.3.3, Table 41 | | | | | | | | |

Five adverse events with the potential for airway obstruction were reported and all occurred in the 12 DU treatment arm. Four of these five subjects were discontinued from the study as summarized in the following table.

| Table 19 Local swelling with potential for airway obstruction - Phase 2 and Phase 3 trials¹ | | | | | | | |
|--|---------------------|--------------------|---------------------------------------|----------------------|----------------|---------------------|----------------|
| Study/Subject ID | Demographics | Onset (Day) | Last recorded study drug (Day) | Adverse Event | Serious | Action Taken | Outcome |
| Active treatment: MK-8237 12 DU | | | | | | | |
| 001 / 120147 | 19 y W F | 7 | 7 | Throat tightness | N | Discontinued | Resolved |
| 001 / 220835 | 42 y B F | 12 | 263 | Pharyngeal oedema | N | None | Resolved |
| 014 / 1483 | 55 y W F | 2 | 6 | Oedema mouth | N | Discontinued | Resolved |
| 014 / 1639 | 21 y W M | 38 | 71 | Tongue oedema | N | Discontinued | Resolved |
| 015 / 1395 | 34 y W F | 15 | 25 | Oedema mouth | N | Discontinued | Resolved |
| Placebo: No reports of local swelling with potential for airway obstruction | | | | | | | |
| 1. All randomized subjects except MT-02 where only those randomized to MK-8237 (6 DU) and placebo are included. From 125592.0, Module 2.5, Table 16 | | | | | | | |

Other events of interest

Asthma

Subjects with a history of asthma were eligible for the trials, provided their asthma was stable: no exacerbations within three months of initiating study drug, a forced expiratory volume in 1 second (FEV1) $\geq 70\%$ of predicted (MT-06 and P003) and $\geq 80\%$ (P001), and did not require maintenance with high-dose inhaled corticosteroids.

Phase 1 trials (MT-01 and MT-03) were conducted in subjects with asthma, a population that is potentially at increased risk for adverse events. The Phase 2 asthma trial, MT-02, evaluated 1, 3 and 6 DU doses of MK-8237, in subjects with asthma. Doses higher than 6 DU were not assessed due to a potential safety concern with the trial design which used steroid tapering while subjects were on MK-8237 treatment.

The subsequent Phase 3 trial, MT-04, is the only study in the Phase 2 and Phase 3 safety database to evaluate the proposed dose of 12 DU (as well as 6 DU) exclusively in an asthmatic population. The study prescribed inhaled corticosteroids for 7-12 months with reduction and withdrawal over a 6 month period.

Study entry requirements for the Phase 3 trial included HDM-induced asthma treated according to GINA Guidelines and FEV1 $\geq 70\%$ of the predicted value. Individuals were excluded if they had a history of persistent allergic asthma or rhinitis caused by an allergen other than HDM to which they were regularly exposed and sensitized or a history of intermittent allergic asthma or allergic rhinitis with the seasonal allergen causing symptoms in the period of the year corresponding to the ICS reduction period (period 3; October to April); previous treatment with immunotherapy with HDM allergen for more than 1 month within the last 5 years; a history of chronic sinusitis (>3 months) or hospitalisations for more than 12 hours due to an asthma exacerbation within the last 3 months prior to screening visit.

The population was overwhelmingly White (99%), with a median age of 31 years (17.0 – 83.0).

Although MT-04 describes equal randomization (1:1:1) following screening, there were 2 more subjects enrolled in the placebo group and 7 more enrolled in the 12 DU group vs. the 6 DU group.

House Dust Mites (*Dermatophagoides farinae* and *Dermatophagoides pteronyssinus*) Allergen Extract
(MK-8237) Proposed Trade Name: ODACTRAM

During period 3, sixty-five of the eighty-one “other” reasons for discontinuation (80%) were due to asthma exacerbations; the remaining reasons included to travel, use of prohibited medication, or planning of pregnancy.

| Table 20: Subject disposition - MT-04¹ | | | | | | |
|--|----------------------------|------------------------|-----|-----------------------|-----|--------------------------|
| | | 12 DU (N = 282) | | 6 DU (N = 275) | | Placebo (N = 277) |
| Entered period 3 (ICS taper) | | 248 | 88% | 237 | 86% | 257 |
| Completed entire trial ² | | 227 | 80% | 229 | 83% | 237 |
| Discontinuations (entire trial) | | 77 | 27% | 72 | 26% | 68 |
| | Due to AE | 25 | 9% | 12 | 4% | 8 |
| | Due to lack of efficacy | 1 | <1% | 1 | <1% | 2 |
| | Lost to follow-up | 3 | 1% | 6 | 2% | 5 |
| | Noncompliant with protocol | 7 | 2% | 6 | 2% | 8 |
| | Pregnancy | 1 | <1% | 1 | <1% | 6 |
| | Withdrawal of consent | 15 | 5% | 16 | 6% | 13 |
| | Other ³ | 25 | 9% | 30 | 11% | 26 |
| Asthma exacerbation ² | | 19 | 7% | 22 | 8% | 24 |

1. MT-04 is the only Phase 3 study with the population limited to asthmatics, specifically those with HDM-induced asthma
2. Completers defined as either attending final study visit or experiencing asthma exacerbation fulfilling primary study endpoint. During period 3A (ICS reduction), asthma exacerbation did not require discontinuation; subjects could continue in trial up to 3 exacerbations. During period 3B (ICS withdrawal) the protocol required subjects be discontinued following an exacerbation
3. During period 3, 65 of 81 “other” reasons for discontinuation (80%) were due to asthma exacerbations; the remaining reasons included to travel, use of prohibited medication, or planning of pregnancy.
From STN 125592.0, Module 2.7.6, page 70.

No deaths, local allergic reactions compromising the airways, anaphylactic reactions (including anaphylactic shock) or AEs requiring treatment with epinephrine were reported in MT-04.

| Table 21: Overview of safety in MT-04 | | | | | | |
|---|--|--------------------------|------|-------------------------|------|----------------------------|
| | | 12 DU N = 282 | | 6 DU N = 275 | | Placebo N = 277 |
| Any adverse event | | 223 | 79% | 204 | 74% | 175 |
| Serious adverse event | | 7 | 2.5% | 10 | 3.6% | 11 |
| Discontinuation due to a treatment related AE | | 17 | 6% | 9 | 3% | 4 |

From STN 125592.0, Module 2.7.6, page 78.

Potential asthma-related adverse events from Phase 2 and Phase 3 studies were compared by treatment assignment. No safety issue was identified as summarized in the following table.

| Table 22: Asthma-related adverse events - Phase 2 and Phase 3 studies¹ | | | | | | |
|--|--|-----------------------------------|----------|---------------------------------|----------|-----------------------------|
| All events by SOC and for any PT with n > 2 in any of the treatment groups | | | | | | |
| | | MK-8237 12 DU N = 1383 | | MK-8237 6 DU N = 808 | | Placebo N = 1540 |
| | | n | % | n | % | N |
| Subjects ≥1 asthma-related adverse event | | 110 | (8.0) | 82 | (10.1) | 126 |
| General disorders and administration site conditions | | 14 | (1.0) | 2 | (0.2) | 9 |
| Chest discomfort | | 14 | (1.0) | 2 | (0.2) | 9 |
| Respiratory, thoracic and mediastinal disorders | | 99 | (7.2) | 80 | (9.9) | 119 |
| Asthma | | 40 | (2.9) | 44 | (5.4) | 57 |
| Cough | | 35 | (2.5) | 17 | (2.1) | 36 |
| Dyspnoea | | 26 | (1.9) | 21 | (2.6) | 29 |
| Wheezing | | 2 | (0.1) | 4 | (0.5) | 10 |

1. All randomized subjects except MT-02 (MK-8237, 6 DU and placebo arms only). Each subject counted once for each applicable row and column.
From STN 1025592.0, Module 5.3.5.3.3, Table 52

Eosinophilic oesophagitis (EoE)

At the Pre-BLA meeting of 08-SEP-2015, based upon concerns regarding the potential for orally administered allergenic products to induce or exacerbate EoE, the higher prevalence of EoE in atopic patients as compared to the general population, and the identification by the OVR clinical reviewer of 2 cases of EoE in the MK-8237 clinical database (2338 subjects), FDA requested that the sponsor conduct a *post hoc* evaluation of cases of EoE, potential cases of EoE and cases for which EoE had been ruled out.

Two cases of EoE were reported in Phase 2 and/or Phase 3 studies: one in an MT-06 subject receiving 6 DU and a second in a P001 subject treated with 12 DU. Both subjects also reported GERD and were treated with swallowed budesonide/fluticasone and with lansoprazole / omeprazole. The subjects continued on study and subsequently completed the trials. One subject was reported as not recovered from either EoE or GERD at the time of trial completion. The other subject was reported as having recovered both from GERD and EoE.

A search for additional potential cases of EoE in subjects without a reported adverse event of EoE was conducted. This involved review of cases with the following PTs:

abdominal pain upper

dyspepsia

dysphagia

eosinophilic oesophagitis

erosive oesophagitis

gastric disorder

gastritis

gastrooesophageal reflux disease

nausea

odynophagia

oesophageal discomfort

oesophageal irritation

oesophageal pain

oesophageal spasm

oesophagitis

From the review of data from this subset of subjects with the above PTs, potential cases were considered to be those cases in which subjects had documented endoscopic procedures or biopsies suggestive of EoE and/or subjects who were administered swallowed corticosteroids. Using this search strategy, 1 potential case was identified in a placebo-treated subject. The subject had a history of GERD and biopsy confirmed EoE. The subject was treated with lansoprazole and symptoms resolved.

Gastrointestinal disorders - overview

A dose-response was seen with respect to the incidence of adverse events of the upper gastrointestinal tract, including overall gastrointestinal tract adverse events, abdominal pain upper, dyspepsia, gastroesophageal reflux disease, nausea, and oesophageal pain, although relatively higher incidences of upper abdominal pain and of nausea were reported in the placebo group.

Table 23: Adverse events involving upper gastrointestinal tract – Phase 2 and Phase 3 studies¹

| | MK-8237 12 DU N = 1383 | | MK-8237 6 DU N = 808 | | Placebo N = 1540 | |
|--|---------------------------|--------|-------------------------|-------|---------------------|-------|
| | n | % | n | % | N | % |
| Subjects with ≥ 1 upper gastrointestinal tract adverse event | 238 | (17.2) | 47 | (5.8) | 93 | (6.0) |
| Abdominal pain upper | 100 | (7.2) | 10 | (1.2) | 48 | (3.1) |
| Dyspepsia | 34 | (2.5) | 16 | (2.0) | 0 | (0.0) |
| Dysphagia | 18 | (1.3) | 5 | (0.6) | 2 | (0.1) |
| Eosinophilic oesophagitis | 1 | (0.1) | 1 | (0.1) | 0 | (0.0) |
| Erosive oesophagitis | 0 | (0.0) | 0 | (0.0) | 1 | (0.1) |
| Gastric disorder | 0 | (0.0) | 1 | (0.1) | 0 | (0.0) |
| Gastritis | 4 | (0.3) | 4 | (0.5) | 1 | (0.1) |
| Gastroesophageal reflux disease | 23 | (1.7) | 10 | (1.2) | 7 | (0.5) |
| Nausea | 134 | (9.7) | 4 | (0.5) | 62 | (4.0) |
| Odynophagia | 1 | (0.1) | 1 | (0.1) | 0 | (0.0) |
| Oesophageal discomfort | 0 | (0.0) | 1 | (0.1) | 0 | (0.0) |
| Oesophageal irritation | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Oesophageal pain | 4 | (0.3) | 1 | (0.1) | 0 | (0.0) |
| Oesophageal spasm | 1 | (0.1) | 0 | (0.0) | 0 | (0.0) |
| Oesophagitis | 1 | (0.1) | 1 | (0.1) | 0 | (0.0) |

1. All randomized subjects except MT-02 where only those randomized to MK-8237, 6 DU and placebo are included. Every subject is counted a single time for each applicable row and column.

From: STN 125592.0, Module 5.3.5.3.3, Table 60

Use during pregnancy and lactation – all studies

The safety of MK-8237 in pregnant and/or lactating females has not been formally studied and subjects who became pregnant during the course of a clinical trial were to be discontinued from further use of study drug and followed up for outcome of the pregnancy. There were a total of 30 pregnancies reported by 30 randomized subjects. All pregnancies occurred in the Phase 2 and 3 trials. Six complications were reported: 4 spontaneous abortions (1 in the MK-8237, 12 DU group; and 3 in the placebo group), 1 induced abortion (MK-8237, 12 DU group), and 1 placenta praevia haemorrhage (placebo group). All complications were reported as recovered or resolved.

Limitations of the safety database

- Phase 2 and Phase 3 study subjects were overwhelmingly classified as White (87.5%).
- Asthmatics enrolled in Phase 2 and Phase 3 studies were limited to those with mild to moderate, well-controlled disease. Exclusions included:
 - An asthma exacerbation within 3 months of study treatment initiation.
 - Classification of asthma as severe or uncontrolled
 - Use of high-dose inhaled corticosteroids or long-acting beta agonists (LABA)
 - Individuals with a history of anaphylaxis, chronic urticaria or angioedema were excluded.
 - Individuals with a forced expiratory volume in 1 second (FEV_1) < 70% predicted were excluded from studies MT-06 and P003; those with FEV_1 < 80% were excluded from study P001.
- Study designs did not formally take asthma status and severity into account, e.g., by stratification at enrollment.
- In the overall safety database (see Table 3, above), the imbalance in the proportion of subjects with asthma (49.6% in 12 DU group, 73.5% in 6 DU group and 56.4% in the placebo group) limits the ability to interpret between group differences.
- Subjects who were pregnant, not using adequate contraception or breast-feeding were excluded from participation in the studies.
- Long-term safety has not been studied (mean and median exposure in combined Phase 2 and Phase 3 studies were both less than 1 year).
- Safety in children has not been adequately studied, but a pediatric study is planned to begin after US licensure in adults.

5. Postlicensure Safety Review**a. Post-market Safety Update Report (PSUR)**

A PSUR covering the period 15 April-2015 to 09-April-2016, submitted as amendment #8, was received by FDA on 08-JUNE-2016.

During the reporting period, the HDM SLIT-tablet was approved in Belgium (Special License), and Australia (via Authorised Prescriber Program and Special Access Scheme). In September 2015, the HDM SLIT-tablet, licensed by ALK to Torii Pharmaceutical Co., Ltd. under the trade name of MITICURE™, was approved for use in Japan (10,000 JAU [equivalent to 6 SQ-HDM] and 3,300 [2 SQ-HDM]). MITICURE is indicated in adults and adolescents (≥12 years) as hyposensitization therapy (allergy immunotherapy) for the treatment of allergic rhinitis caused by house dust mites.

As of 09-April-2016, the product had been launched in Germany, Denmark, Austria and Japan.

HDM SLIT-tablet postmarketing information is available from market introduction, 23-September-2015, to 09-Apr-2016, and is based upon spontaneous and non-interventional postmarketing reports for MK-8237 managed in the Merck Adverse Reporting and Review System (MARRS) database. The MARRS database was queried on 26-April-2016 for reports received from healthcare providers (HCP) from 23-Sep-2015 to 09-Apr-2016.

A total of 149 spontaneous and non-interventional HCP confirmed postmarketing reports (12 serious) of 407 events (30 serious) were identified. There were no reports with a fatal outcome. Reports were received from Germany (n=111), Japan (n=33), Denmark (n=4), and Austria (n=1).

Among the 407 total events, the preferred terms (PTs) of the five most frequently reported AEs were: mouth swelling (n=29), oral pruritus (n=25), throat irritation (n=23), lip swelling (n=20), paraesthesia oral (n=18), and dyspnoea (n=18).

Among the 30 serious events, there were 2 events each of lip swelling, mouth swelling, and swollen tongue. Each of the remaining 24 events was reported once. Those PTs were as follows: abdominal pain upper, anaphylactic reaction, angioedema, chronic sinusitis, dysphagia, dyspnoea, epiglottic oedema, erythema, eyelid oedema, facial bones fracture, hyperplasia, hypertensive crisis, laryngeal oedema, nasal septum deviation, palatal swelling, paraesthesia, paraesthesia oral, respiratory distress, sinusitis, swelling face, throat irritation, tongue oedema, tonsillar hypertrophy, and vomiting.

Important identified and potential risks

Serious reports possibly associated with the important identified and potential risks within the pharmacovigilance plan for MK-8237:

- Systemic Allergic Reactions Including Anaphylactic Reactions
Queried PTs: anaphylactic reaction, angioedema, hypersensitivity, and drug hypersensitivity

Serious reports retrieved: anaphylactic reaction (n=1) and angioedema (n=1).

- Local allergic reactions with potential to compromise airway
Queried PTs: dysphonia, oedema mouth, laryngeal oedema, oropharyngeal swelling, palatal oedema, pharyngeal oedema, throat tightness, tongue oedema, upper airway obstruction, stridor, and choking sensation

Serious reports retrieved: tongue oedema (n=1), laryngeal oedema (n=1), throat tightness and dysphonia (n=1).

- Acute worsening of Asthma
Queried PTs: asthma, asthmatic crisis, and status asthmaticus

Serious reports retrieved: None

- Anaphylactic Shock

Queried PTs: anaphylactic shock, circulatory collapse, shock, and shock syndrome

Serious reports retrieved: None

- Eosinophilic Esophagitis

Queried PTs: eosinophilic esophagitis

Serious reports retrieved: None

Epinephrine utilization

The narratives for the 149 reports were reviewed for use of epinephrine, No use was reported.

Sponsor's evaluation of SUR data:

No new safety signals have been identified based on postmarketing use for the period queried. The safety data presented during the period of this SUR remain consistent with the safety data presented in the original marketing application and do not change the overall risk/benefit conclusions provided in the original marketing application.

b. Post-approval studies outside the US

A post-approval pediatric investigational plan (PIP) to include two pediatric studies, one for treatment of allergic rhinitis and one for the prevention of asthma, both enrolling children 5 years to less than 18 years of age in Europe, is scheduled for completion by December 2028.

A post-approval phase 3 study of pediatric patients 5-11 years of age is planned to enroll approximately 400 subjects in Japan. No schedule is provided.

6. Integrated Risk Assessment

- a. Description of important safety issues identified by the FDA reviewer from any source that does not trigger a PMR or REMS
 - i. Safety assessments should be based on actual treatment received, regardless of treatment assigned rather than an "as randomized" or intent-to-treat population. Specifically, Studies P014 and P015 used the Full Analysis Set for safety analyses, and for Study P012, it was decided, after unblinding, to analyze subjects as randomized. However, the pre-specified statistical plan for Study P012 called for safety analyses to be performed based on the actual treatment received.
 - ii. The clinical development plan has shown that this oral allergen product has the potential to cause allergic reactions largely manifested by local oropharyngeal and upper gastrointestinal adverse events, similar to other licensed SLIT products, GRASTEK and RAGWITEK. Significant increases in serious or life-threatening allergic-type adverse events were not reported in the clinical studies, but the studies were relatively small, enrolled healthy younger adults (median age 31 years) who are likely to have had low background rates of chronic cardiovascular or respiratory conditions, and excluded individuals with the following conditions or history who may be treated with the product once it is licensed:

- severe, persistent asthma
- use of high-dose inhaled corticosteroids
- use of long-acting beta agonists
- history of severe allergic reactions, anaphylaxis and/or angioedema

The sponsor proposes to mitigate risks in asthmatics and those with pertinent histories through routine pharmacovigilance, safety surveillance for signal detection, selected event-specific follow-up questionnaires, labeling and a patient medication guide.

- b. Signals identified by the reviewer from any source that trigger a PMR or REMS: None
- c. This reviewer has no additional comments on the submitted Postmarketing Commitment protocol synopsis: Post-Market Claims and EMR Based Study of Serious Allergic Reactions and Eosinophilic Esophagitis in Marketed Use of MK-8237 in the United States.
- d. Final determination of the safety profile of the product used in the studies submitted to this BLA is pending final clinical, statistical and/or product reviews.

7. Recommendation

Based upon the submitted information and current clinical knowledge, at this time OBE/DE requests that the sponsor:

- c. Explain why safety data analysis did not following the pre-specified data analysis plan for P012.
- d. Provide the following information for any subjects in any Phase 2 or 3 study who crossed over to a treatment arm to which they were not assigned:
 - i. Study name
 - ii. Randomized treatment assignment
 - iii. Actual treatment(s) received by study day
 - iv. A description of adverse events experienced by subject, including onset by study day, whether the AE was classified as serious, and the AE outcome.
- a. Routine pharmacovigilance will include:
 - i. Event-specific questionnaires to be used to follow-up reports of:

Important identified safety issues:

- Serious systemic allergic reactions, including anaphylactic reactions
- Local allergic reactions with potential to compromise airway
- Acute worsening of asthma symptoms (exacerbations)

House Dust Mites (*Dermatophagoides farinae* and *Dermatophagoides pteronyssinus*) Allergen Extract (MK-8237) Proposed Trade Name: ODACTRAM

Important potential safety issues

- Anaphylactic shock
 - Eosinophilic esophagitis (EoE)
- ii. Periodic safety review on all spontaneous postmarketing adverse event reports including those related to important missing information:
- Pregnancy and lactation
 - Use in children (<18 years of age)
 - Use in elderly (> 65 years of age)
 - Use in severe, unstable or uncontrolled asthma
 - Co-administration with other SLIT products
- b. Two postmarket phase 4 studies will be conducted under a single title: “Post-Market Claims and EMR Based Study of Serious Allergic Reactions and Eosinophilic Esophagitis in Marketed Use of MK-8237 in the United States.” One study is based upon health claims from a large US health insurance database and the other study is based on electronic medical records from a large US integrated health system. Together the studies will aim to assess general safety and specifically assess the risks of:
- Systemic allergic reactions, including anaphylactic reactions / anaphylactic shock
 - Serious allergic reactions including local reaction w/ potential to compromise airway
 - Eosinophilic esophagitis (EoE)
 - Acute worsening of asthma symptoms

The studies will be incorporated into the database already being used for GRASTEK and RAGWITEK postmarketing studies. Based upon experience with US uptake of these two products, the sponsor estimates uptake for the DM product at (b) (4) patients over 3 years. Study protocols will be submitted in another submission.

References

Arbes SJ, Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: Results from the Third National Health and Nutrition Examination Survey. *J Allergy Clin Immunol* 2005; 116(2):377-83.

Arlian LG, Morgan MS, Neal JS. Dust mite allergens: Ecology and distribution. *Curr Allergy Asthma Rep* 2002;2(5):401-11.

Barberi S1, Bernardo L, D'Auria E, Ferrara F, Tosi S, Incorvaia C, Buttafava S, Frati F, Ciprandi G. Allergen immunotherapy and respiratory infections in children: an encouraging experience. *Minerva Pediatr*. 2015 Nov 25. [Epub ahead of print]

Bernstein IL, Li JT, Bernstein DI, Hamilton R, Spector S, Tan R, Sicherer S, Golden D, Khan D, Nicklas R, Portnoy J, Blessing-Moore J, Cox L, Lang DM, Oppenheimer J, Randolph CC, Schuller DE, Tilles SA, Wallace DV, Levetin E, Weber R. Allergy Diagnostic Testing: An Updated Practice Parameter.; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology. *Ann Allergy Asthma Immunol* 2008 Mar;100(3 Suppl 3):S1-148

Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008. *Allergy* 2008;63(Suppl. 86):7-160.

Bousquet PJ, Cox LS, Durham SR, Nelson HS, Passalacqua G, Ryan DP, et al. Sub-lingual Immunotherapy: World Allergy Organization Position Paper 2009. *World Allergy Organ J* 2009;2(11):233-81.

Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, Nelson H, Adkiss CA. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. *Allergy Clin Immunol*. 2013 May;131(5):1288-96.e3.

Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. *World Allergy Organ J* 2014;7(6):1-52.

Cox L, Nelson H, Lockey R, Nelson H. Eds. Allergen immunotherapy: A practice parameter third update. *J Allergy Clin Immunol* 2011; 127 (suppl):S1-55.

Creticos P. Sublingual immunotherapy for allergic rhinoconjunctivitis and asthma. UpToDate. Last updated May 26, 2016.

Dunsky EH, Goldstein MF, Dvorin DJ, Belecanec GA. Anaphylaxis to sublingual immunotherapy. *Allergy* 2000;61:1235.

Klimek L, Mosbech H, Ziegelmayer P, Rehm D, Stage BS, Demoly P. SQ house dust mite (HDM) SLIT-tablet provides clinical improvement in HDM-induced allergic rhinitis. *Expert Rev Clin Immunol*. 2016 Apr;12(4):369-77.

Lieberman JA, Chehade M. Eosinophilic esophagitis: diagnosis and management. *Immunol Allergy Clin North Am*. 2012. Feb;32(1):67-81.

Lin Z, Liu Q, Li T, Chen D, Chen D, Xu R. The effects of house dust mite sublingual immunotherapy in patients with allergic rhinitis according to duration. *Int Forum Allergy Rhinol*. 2016 Jan;6(1):82-7. Epub 2015 Nov 17.

National Academy of Sciences. Clearing the air: asthma and indoor air exposures. Washington, DC: National Academy Press; c2000. Chapter 5, Indoor biologic exposures; p. 105-222.

Normansell R, Kew KM, Bridgman A. Sublingual immunotherapy for asthma. *Cochrane Database Syst Rev*. 2015 Aug 28; (8):CD011293.

Passalacqua G, Valentina G, Scifo F, Canonica GW. Sublingual Immunotherapy for Allergic Rhinitis and Conjunctivitis. *Immunotherapy*. 2013; 5(3): 257-264.

Portnoy J, Miller JD, Williams PB, Chew GL, Miller JD, Zaitoun F, et al. Environmental assessment and exposure control of dust mites: a practice parameter. *Ann Allergy Asthma Immunol* 2013;111:465-507.

Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. *Cochrane Database Syst Rev*. 2010 Dec 8; (12):CD002893.

House Dust Mites (*Dermatophagoides farinae* and *Dermatophagoides pteronyssinus*) Allergen Extract (MK-8237) Proposed Trade Name: ODACTRAM

Rank MA, Oslie CL, Krogman JL, Park MA, Li JT. Allergen immunotherapy safety: Characterizing systemic reactions and identifying risk factors. *Allergy Asthma Proc* 2008;29:400-5.

Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TAE. Survey of fatalities from skin testing and immunotherapy 1985-1989. *J Allergy Clin Immunol* 1993;92:6-15.

Rodríguez-Pérez N, Ambriz-Moreno Mde J, Canonica GW, Penagos M. Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. *Ann Allergy Asthma Immunol*. 2008 Sep;101(3):304-10.

Sampson HA, Muñoz-Furlong A, Bock A, Schmitt C, Bass R, Chowdhury BA, et al. Symposium on the definition and management of anaphylaxis: Summary report. *J Allergy Clin Immunol* 2005;115:584-91.

Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson Jr., NF, Bock, SA, Branum, A. et. al. Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. *J Allergy Clin Immunol*, 117 (2006), pp. 391–397.

Thomas WR. Geography of house dust mite allergens. *Asian Pac J Allergy Immunol*. 2010 Dec;28(4):211-24.

Virchow JC, Backer V, Kuna P, Prieto L, Nolte H, Villesen HH, Ljørring C, Riis B, de Blay F. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. *JAMA*. 2016 Apr 26;315(16):1715-25.

Addendum to OBE/DE Review

In response to OBE/DE concerns as described Items 7. a. Integrated Risk Assessment and 8. Recommendations, above, communicated in the FDA Information Request of December 14, 2016, the sponsor has submitted their response, STN 125592.0.48.

1. For Study P012, the Statistical Analysis Plan described a procedure for including subjects in the safety analysis based on treatment group allocation dependent on whether the erroneous dose was placebo or a dose lower than/equal to versus higher than the dose to which the subject was randomized. Of the four subjects reported as having received treatment other than that to which they were randomized, all subjects received MK-8237, including one whose randomization number actually corresponded to the same treatment group as the wrong treatment taken, and therefore was actually treated as randomized.

Only one subject received a higher dose:

This subject was randomized to the 1 DU treatment group but actually received 6 DU from between Study Days 290 and 415, although the exact start and end dates of the erroneous treatment are not known. This subject experienced 2 adverse events – both prior to the dispensing of the incorrect dose: asthma (duration 7 days) and upper respiratory tract infection (duration 19 days). Both were characterized by the sponsor as “mild.”

2. Subjects in Phase 2 and Phase 3 trials (except P012, discussed above) receiving treatment other than as assigned.

| Table A: Adverse events in subjects who received a treatment to which they were not assigned ¹ | | | | | | | | |
|---|------------------------------------|---------------------|-------------------------|--------------------|-------------------|-------------------|---------|----------------------------------|
| Study | Subject ID Planned Treatment | Erroneous Treatment | | | Adverse Event | | | |
| | | Received | Start - End (Relday) | Duration (Days) | Term | Onset (Relday) | Serious | Outcome |
| P001 | 014600006 MK-8237 12 DU | Placebo | 30 - 39 | 10 | Ear pruritus | 1 | N | Recovered/Resolved |
| | | | | | Glossodynia | 1 | N | Recovered/Resolved |
| | | | | | Lip swelling | 1 | N | Recovered/Resolved |
| | | | | | Oral pruritus | 1 | N | Recovered/Resolved |
| | | | | | Throat irritation | 1 | N | Recovered/Resolved |
| | | | | | Ear pruritus | 7 | N | Recovered/Resolved |
| | | | | | Throat irritation | 7 | N | Recovered/Resolved |
| | 005500008 MK-8237 12 DU | Placebo | 216 - 228 | 13 | Palatal swelling | 1 | N | Recovered/Resolved |
| | | | | | Throat irritation | 1 | N | Recovered/Resolved |
| | | | | | Ear pruritus | 1 | N | Recovered/Resolved with Sequelae |
| | | | | | Oral pruritus | 1 | N | Recovered/Resolved with Sequelae |
| | | | | | Nausea | 6 | N | Recovered/Resolved |
| | | | | | Palatal swelling | 8 | N | Recovered/Resolved with Sequelae |
| | | | | | Pharyngeal oedema | 8 | N | Recovered/Resolved |
| | | | | | Pharyngeal oedema | 11 | N | Recovered/Resolved |
| | | | | | Throat irritation | 17 | N | Recovered/Resolved |
| | | | | | Ear pruritus | 25 | N | Recovered/Resolved |
| | | | | | Throat irritation | 26 | N | Recovered/Resolved with Sequelae |
| | | | | | Ear pruritus | 29 | N | Recovered/Resolved |
| | | | | | Lip swelling | 51 | N | Recovered/Resolved |

Table A: Adverse events in subjects who received a treatment to which they were not assigned¹

| | | | | | | | | |
|-------|------------------------|---------------|-----------|------|-----------------------------------|-------|-----|----------------------|
| | 002400027 Placebo | MK-8237 12 DU | 245 – 266 | 22 | Throat irritation | 1 | N | Recovered/Resolved |
| | | | | | Oral pruritus | 2 | N | Recovered/Resolved |
| | | | | | Oral pruritus | 3 | N | Recovered/Resolved |
| | | | | | Nasopharyngitis | 294 | N | Recovered/Resolved |
| | 010100010 Placebo | MK-8237 12 DU | 1– 30 | 30 | Sinus congestion | 25 | N | Recovered/Resolved |
| | | | | | Asthma | 365 | N | Recovering/Resolving |
| | 011700016 Placebo | MK-8237 12 DU | 190 – 224 | 35 | Abdominal pain upper | 1 | N | Recovered/Resolved |
| | | | | | Mouth ulceration | 13 | N | Recovered/Resolved |
| | | | | | Rash | 182 | N | Recovered/Resolved |
| | | | | | Acute sinusitis | 182 | N | Recovered/Resolved |
| MT-02 | 50965 MK-8237 1 DU | MK-8237 6 DU | 290 – 415 | 66§† | Asthma | 53 | N | Recovered |
| | | | | | Upper Respiratory Tract Infection | 134 | N | Recovered |
| | 50968 MK-8237 3 DU | MK-8237 1 DU | 266 – 287 | 12§ | Upper Respiratory Tract Infection | 349 | N | Recovered |
| | | | | | | | | |
| | 51092 MK-8237 6 DU | MK-8237 3 DU | 159 - 194 | 20§† | Sinusitis | -164# | N | Recovered |
| | | | | | Blepharoplasty | -37# | N | Recovered |
| | | | | | Sinusitis | 41 | N | Recovered |
| | | | | | Lower Respiratory Tract Infection | 82 | N | Recovered |
| | | | | | Lower Respiratory Tract Infection | 196 | N | Recovered |
| | | | | | Pharyngolaryngeal pain | 248 | N | Recovered |
| | | | | | Lower Respiratory Tract Infection | 289 | N | Recovered |
| MT-04 | 50261 MK-8237 12 DU | MK-8237 6 DU | 197 - 281 | 84§ | Dyspepsia | 209 | N | Recovered |
| MT-06 | 50600 Placebo | MK-8237 12 DU | 93 - 113 | 21 | No AEs reported | --- | --- | --- |

§ In the period of erroneous treatment this number of tablets was from the erroneous IMP box (based on tablet accountability)

Before first IMP;

□ Start date reported as unknown – set to the first day of the month

† Exact dates of erroneous treatment unknown; hence end date of treatment is next visit date. Subject took the number of erroneous treatments between visits.

1. No subjects in Study P003 received incorrect study treatment, i.e., other than that to which they were assigned.

Conclusion:

1. The sponsor has provided adequate information in their response to address OBE/DE concerns.
2. The adverse events occurring in subjects who were crossed over to treatment other than that to which they were assigned include: 1. A variety of transient, non-specific, non-serious events expected to occur in a healthy population; and 2. Events consistent with those associated with administration of MK-8237 as well as other sub-lingual immunotherapy products, i.e., local allergic-type reactions.
3. No new safety signals were identified in review of the data submitted in STN 125592.0.48.
4. OBE/DE agrees that the sponsor proposed postmarket pharmacovigilance plan is acceptable should this product be licensed for use in adults 18-65 years of age.